WO2022140702A1 - Compositions of modified trems and uses thereof - Google Patents

Compositions of modified trems and uses thereof Download PDF

Info

Publication number
WO2022140702A1
WO2022140702A1 PCT/US2021/065159 US2021065159W WO2022140702A1 WO 2022140702 A1 WO2022140702 A1 WO 2022140702A1 US 2021065159 W US2021065159 W US 2021065159W WO 2022140702 A1 WO2022140702 A1 WO 2022140702A1
Authority
WO
WIPO (PCT)
Prior art keywords
trem
binding moiety
independently
absent
asgpr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/065159
Other languages
English (en)
French (fr)
Inventor
Theonie ANASTASSIADIS
David Charles Donnell BUTLER
Neil KUBICA
Qingyi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Inc
Original Assignee
Flagship Pioneering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Inc filed Critical Flagship Pioneering Inc
Priority to AU2021409740A priority Critical patent/AU2021409740A1/en
Priority to CA3206285A priority patent/CA3206285A1/en
Priority to BR112023012377A priority patent/BR112023012377A2/pt
Priority to US18/269,450 priority patent/US20240175020A1/en
Priority to MX2023007630A priority patent/MX2023007630A/es
Priority to KR1020237025192A priority patent/KR20230135585A/ko
Priority to JP2023538736A priority patent/JP2024501288A/ja
Priority to CN202180094267.XA priority patent/CN117083383A/zh
Priority to IL303886A priority patent/IL303886A/en
Priority to EP21854913.7A priority patent/EP4267732A1/en
Publication of WO2022140702A1 publication Critical patent/WO2022140702A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Definitions

  • BACKGROUND tRNAs are complex RNA molecules that possess a number of functions including the ability to initiate and elongate proteins.
  • the present disclosure features, inter alia, a tRNA-based effector molecule (TREM) entity comprising an asialoglycoprotein receptor (ASGPR) binding moiety, as well as compositions and methods of use thereof.
  • the ASGPR binding moiety may be conjugated to a nucleobase within the TREM entity, or within an intemucleotide linkage of the TREM entity, or at a terminus (e.g., the 5’ or 3’ terminus) of the TREM entity.
  • the TREM entity comprises a TREM, a TREM Core Fragment, or a TREM Fragment.
  • the nucleobase comprises adenine, thymine, cytosine, guanosine, or uracil, or a variant or modified form thereof.
  • the TREM entity (e.g., TREM) described herein comprises the sequence of Formula A: [L 1 ]-[ASt Domainl]-[L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2] (A), wherein, independently, the TREM comprises an ASGPR binding moiety.
  • the ASGPR binding moiety comprises an ASGPR carbohydrate and an ASGPR linker.
  • the ASGPR binding moiety comprises a galactose (Gal) and/or N-acetylgalactosamine (GalNAc) moiety.
  • the ASGPR binding moiety comprises a plurality of Gal and/or GalNAc moieties (e.g., 2, 3, 4, 5, 6, 7, 8, or more Gal and/or GalNAc moieties). In an embodiment, the ASGPR binding moiety comprises a triantennary GalNAc moiety.
  • the TREM further comprises a chemical modification (e.g., a phosphothiorate intemucleotide linkage, or a 2 ’-modification on a ribose moiety within the TREM).
  • the ASGPR binding moiety is present on a nucleobase within a nucleotide in the TREM. In an embodiment, the ASGPR binding moiety is present on the 5’ terminus of the TREM. In an embodiment, the ASGPR binding moiety is present on the 3’ terminus of the TREM.
  • the ASGPR binding moiety is present in a TREM domain selected from L1, ASt Domain 1, L2, DH Domain, L3, ACH Domain, VL Domain, TH Domain, L4, and ASt Domain2.
  • the ASGPR binding moiety is present in the L1 region.
  • the ASGPR binding moiety is present in the AST Domainl.
  • the ASGPR binding moiety is present in the L2 region.
  • the ASGPR binding moiety is present in the DH Domain.
  • the ASGPR binding moiety is present in the L3 region.
  • the ASGPR binding moiety is present in the ACH Domain.
  • the ASGPR binding moiety is present in the VL Domain.
  • the ASGPR binding moiety is present in the TH Domain.
  • the ASGPR binding moiety is present in the L4 region.
  • the ASGPR binding moiety is present in the AST Domain2.
  • the TREM comprising an ASGPR binding moiety retains the ability to support protein synthesis, be charged by a synthetase, be bound by an elongation factor, introduce an amino acid into a peptide chain, support elongation, and/or support initiation.
  • the TREM comprising an ASGPR binding moiety comprises at least X contiguous nucleotides without a chemical modification, wherein X is greater than 10.
  • the TREM comprising an ASGPR binding moiety comprises no more than 5, 10, or 15 nucleotides of a type (e.g., A, T, C, G or U) that do not comprise chemical modification.
  • the TREM comprising an ASGPR binding moiety comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, or 80 nucleotides of a type (e.g., A, T, C, G or U) that do not comprise a chemical modification.
  • the TREM comprising an ASGPR binding moiety comprises at least X contiguous nucleotides comprising a chemical modification, wherein X is greater than 10.
  • the TREM comprising an ASGPR binding moiety comprises more than 5, 10, or 15 nucleotides of a type (e.g., A, T, C, G or U) that comprise a chemical modification.
  • the TREM comprising an ASGPR binding moiety comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, or 80 nucleotides of a type (e.g., A, T, C, G or U) that comprise a chemical modification.
  • the chemical modification is a naturally occurring chemical modification or a non- naturally occurring chemical modification (e.g., a phosphothiorate intemucleotide linkage or a 2’ -modification on a ribose moiety within the TREM).
  • the chemical modification comprises a fluorophore.
  • a TREM comprising an ASGPR binding moiety, or a composition thereof, described herein may be used to modulate a production parameter (e.g., an expression parameter and/or a signaling parameter) of an RNA corresponding to, or a polypeptide encoded by, a nucleic acid sequence comprising an endogenous open reading frame (ORF) having a premature termination codon (PTC).
  • a production parameter e.g., an expression parameter and/or a signaling parameter
  • ORF endogenous open reading frame
  • PTC premature termination codon
  • a TREM comprising an ASGPR binding moiety, or a composition thereof, described herein may be used in a method of modulating a production parameter of an mRNA corresponding to, or polypeptide encoded by, an endogenous open reading frame (ORF) in a subject, which ORF comprises a premature termination codon (PTC), contacting the subject with a TREM comprising an ASGPR binding moiety or a composition thereof in an amount and/or for a time sufficient to modulate the production parameter of the mRNA or polypeptide, wherein the TREM comprising an ASGPR binding moiety has an anticodon that pairs with the codon having the first sequence, thereby modulating the production parameter in the subject.
  • the production parameter comprises a signaling parameter and/or an expression parameter, e.g., as described herein.
  • a TREM comprising an ASGPR binding moiety, or a composition thereof, described herein may be used in a method of treating a subject having an endogenous open reading frame (ORF) which comprises a premature termination codon (PTC), comprising providing a TREM comprising an ASGPR binding moiety, or a composition thereof, wherein the TREM comprising an ASGPR binding moiety comprises an anticodon that pairs with the PTC in the ORF; contacting the subject with the TREM comprising an ASGPR binding moiety or a composition thereof in an amount and/or for a time sufficient to treat the subject, thereby treating the subject.
  • the PTC comprises UAA, UGA or UAG.
  • a TREM comprising an ASGPR binding moiety, or a composition thereof, described herein may be used in a method of treating a subject having an disease or disorder associated with a premature termination codon (PTC), comprising providing a TREM comprising an ASGPR binding moiety or a composition described herein; contacting the subject with the TREM comprising an ASGPR binding moiety or a composition thereof in an amount and/or for a time sufficient to treat the subject, thereby treating the subject.
  • the PTC comprises UAA, UGA or UAG.
  • the disease or disorder associated with a PTC is a disease or disorder described herein, e.g., a cancer or a monogenic disease.
  • TREMs any of the aforesaid TREM entities
  • TREMs e.g., TREMs, TREM core fragments, TREM Fragments, TREM compositions, preparations, methods of making TREM compositions and preparations, and methods of using TREM compositions and preparations
  • TREMs and preparations include one or more of the following enumerated embodiments.
  • FIGS. 1 A-l J are images that depict ASGPR-expressing U2OS cells transfected with exemplary TREMs comprising an ASGPR binding moiety described herein.
  • uptake of the TREMs comprising a SEQ ID NO. 650 backbone with ASGPR binding moieties at various positions along the sequence and conjugated to Cy3 was monitored and visualized by fluorescent microscopy.
  • FIG. 2 is a graphical representation of the fluorescent microscopy results of FIGs. 1A-1J. The results are depicted as the average intensity over the concentration of oligo (nM) given to the cells.
  • FIGs. 3 A-3H are images that depict ASGPR-expressing U2OS cells transfected with exemplary TREMs comprising an ASGPR binding moiety described herein.
  • uptake of the TREMs comprising a SEQ ID NO. 650 backbone with ASGPR binding moieties at various positions along the sequence and conjugated to Cy3 was monitored and visualized by fluorescent microscopy.
  • FIG. 4 is a graphical representation of the fluorescent microscopy results of FIGs. 3A-3H. The results are depicted as the average intensity over the concentration of oligo (nM) given to the cells.
  • FIGs. 5A-5J are images that depict ASGPR-expressing U2OS cells transfected with exemplary TREMs comprising an ASGPR binding moiety described herein.
  • uptake of the TREMs comprising a SEQ ID NO. 622 backbone with ASGPR binding moieties at various positions along the sequence and conjugated to Cy3 was monitored and visualized by fluorescent microscopy.
  • FIG. 6 is a graphical representation of the fluorescent microscopy results of FIGs. 5A-5J. The results are depicted as the average intensity over the concentration of oligo (nM) given to the cells.
  • FIGs. 7A-7J are images depicting uptake of exemplary TREMs comprising an ASGPR binding moiety as described herein by primary human hepatocytes.
  • uptake of the TREMs comprising a SEQ ID NO. 650 backbone with ASGPR binding moieties at various positions along the sequence and conjugated to Cy3 was monitored and visualized by fluorescent microscopy.
  • FIG. 8 is a graphical representation of the fluorescent microscopy results of FIGs. 7A-7J. The results are depicted as the average intensity over the concentration of oligo (nM) given to the cells.
  • FIGs. 9A-9H are images depicting uptake of exemplary TREMs comprising an ASGPR binding moiety as described herein by primary human hepatocytes.
  • uptake of the TREMs comprising a SEQ ID NO. 653 backbone with ASGPR binding moieties at various positions along the sequence and conjugated to Cy3 was monitored and visualized by fluorescent microscopy.
  • FIG. 10 is a graphical representation of the fluorescent microscopy results of FIGs. 9A-9H. The results are depicted as the average intensity over the concentration of oligo (nM) given to the cells.
  • FIGs. 11 A-11 J are images depicting uptake of exemplary TREMs comprising an ASGPR binding moiety as described herein by primary human hepatocytes.
  • uptake of the TREMs comprising a SEQ ID NO. 622 backbone with ASGPR binding moieties at various positions along the sequence and conjugated to Cy3 was monitored and visualized by fluorescent microscopy.
  • FIG. 12 is a graphical representation of the fluorescent microscopy results of FIGs.l 1A- 11 J. The results are depicted as the average intensity over the concentration of oligo (nM) given to the cells.
  • FIG. 13 is a graph depicting the results of exemplary TREM uptake by ASGPR- expressing U2OS cells transfected with a nLUC-premature terminating codon (PTC) reporter.
  • the exemplary TREMs comprising a SEQ ID NO. 650 backbone comprising an ASGPR-binding moiety at a position along the sequence were transfected using RNAiMAX transfection reagent. The results are shown as fold-change over the mock (no TREM) sample.
  • FIG. 14 is a graph depicting the results of exemplary TREM uptake by ASGPR- expressing U2OS cells transfected with a nLUC-premature terminating codon (PTC) reporter.
  • the exemplary TREMs comprising a SEQ ID NO. 653 backbone comprising a ASGPR binding moiety at a position along the sequence were transfected using RNAiMAX transfection reagent. The results are shown as fold-change over the mock (no TREM) sample.
  • FIG. 15 is a graph depicting the results of exemplary TREM uptake by ASGPR- expressing U2OS cells transfected with a nLUC-premature terminating codon (PTC) reporter.
  • the exemplary TREMs comprising a SEQ ID NO. 622 backbone comprising a ASGPR binding moiety at a position along the sequence were transfected using RNAiMAX transfection reagent. The results are shown as fold-change over the mock (no TREM) sample.
  • TREM tRNA-based effector molecule
  • TREM tRNA-based effector molecule
  • ASGPR asialoglycoprotein receptor
  • TREM entities e.g., TREMs
  • TREMs are complex molecules which can mediate a variety of cellular processes.
  • Pharmaceutical TREM compositions e.g., TREMs comprising an ASGPR binding moiety, can be administered to a cell, a tissue, or to a subject to modulate these functions.
  • an AStD comprises an ASt Domain 1 and an ASt Domain 2.
  • ASt Domain 1 is at or near the 5’ end of the TREM and the ASt Domain 2 is at or near the 3’ end of the TREM.
  • An AStD comprises sufficient RNA sequence to mediate, e.g, when present in an otherwise wildtype tRNA, acceptance of an amino acid, e.g, its cognate amino acid or a non-cognate amino acid, and transfer of the amino acid (AA) in the initiation or elongation of a polypeptide chain.
  • the AStD comprises a 3 ’-end adenosine (CCA) for acceptor stem charging which is part of synthetase recognition.
  • CCA 3 ’-end adenosine
  • the AStD has at least 75, 80, 85, 85, 90, 95, or 100% identity with a naturally occurring AStD, e.g., an AStD encoded by a nucleic acid in Table 1.
  • the TREM can comprise a fragment or analog of an AStD, e.g., an AStD encoded by a nucleic acid in Table 1, which fragment in embodiments that has AStD activity and in other embodiments do not have AStD activity.
  • the ASGPR binding moiety is present within the AStD.
  • the ASGPR binding moiety is bound to a nucleobase within a nucleotide in the AStD.
  • the ASGPR binding moiety is present within the intemucleotide linkage in the AStD.
  • the ASGPR binding moiety is present on a terminus (e.g., the 5’ or 3’ terminus) within the AStD.
  • the ASt Domain 1 comprises positions 1-9 within the TREM sequence.
  • the ASGPR binding moiety is present within ASt Domainl (e.g., positions 1-9) within the TREM sequence.
  • the ASt Domain2 comprises positions 65-76 within the TREM sequence.
  • the ASPGR binding moiety is present within the ASt Domain 1 (e.g., positions 65-76) within the TREM sequence.
  • AStD falls under the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the ASPGR binding moiety is present with the AStD which falls under the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the AStD comprises residues R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 (an exemplary ASt Domian2) and residues R 65 -R 66 -R 67 -R 68 -R 69 -R 70 -R 71 (an exemplary ASt Domian2) of Formula I ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula I ZZZ refers to all species.
  • the AStD comprises residues R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 and residues R 65 -R 66 -R 67 -R 68 -R 69 -R 70 -R 71 of Formula II ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula II ZZZ refers to mammals.
  • the AStD comprises residues R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 and residues R 65 - R 66 -R 67 -R 68 -R 69 -R 70 -R 71 of Formula III ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula III ZZZ refers to humans.
  • ZZZ indicates any of the amino acids: Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamine, Glutamate, Glycine, Histidine, Isoleucine, Methionine, Leucine, Lysine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, or Valine.
  • an “anticodon hairpin domain (ACHD)” refers to a domain comprising an anticodon that binds a respective codon in an mRNA, and comprises sufficient sequence, e.g., an anticodon triplet, to mediate, e.g., when present in an otherwise wildtype tRNA, pairing (with or without wobble) with a codon.
  • the ACHD has at least 75, 80, 85, 85, 90, 95, or 100% identity with a naturally occurring ACHD, e.g., an ACHD encoded by a nucleic acid in Table 1.
  • the TREM can comprise a fragment or analog of an ACHD, e.g., an ACHD encoded by a nucleic acid in Table 1, which fragment in embodiments has ACHD activity and in other embodiments does not have ACHD activity.
  • the ASGPR binding moiety is present within the ACHD.
  • the ASGPR binding moiety is bound to a nucleobase within a nucleotide in the ACHD.
  • the ACHD comprises positions 27-43 within the TREM sequence.
  • the ASGPR binding moiety is present within the ACHD (e.g., positions 27-43) within the TREM sequence.
  • the ACHD falls under the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the ASGPR binding moiety is present within the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or a sequence that differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the ACHD comprises residues -R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -
  • Formula I ZZZ refers to all species.
  • the ACHD comprises residues -R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -
  • Formula II ZZZ refers to mammals.
  • the ACHD comprises residues -R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -
  • Formula III ZZZ refers to humans.
  • ZZZ indicates any of the amino acids: Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamine, Glutamate, Glycine, Histidine, Isoleucine, Methionine, Leucine, Lysine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, or Valine.
  • the anticodon of a TREM entity comprises three nucleotide residues and pairs with a three nucleotide codon. In an embodiment, the anticodon of a TREM entity consists of three nucleotide residues and pairs with an anticodon which consists of three nucleotide residues. In an embodiment the anticodon of the TREM entity does not pair with a codon having four, five or a larger number of nucleotide residues but pairs only with three codon nucleotide residues.
  • the TREM entity does not alter the reading frame of an mRNA.
  • the anti-codon of a TREM entity pairs with a triplet codon of an mRNA and does not pair with an adjacent nucleotide.
  • use of the TREM entity does not alter the length of the polypeptide transcribed from the mRNA, e.g., it does not suppress a termination codon, e.g., a premature termination codon. In an embodiment, the TREM does not alter the length of the ORF of an mRNA.
  • the ASGPR binding moiety as described herein refers to structure comprising: (i) an ASGPR carbohydrate and (ii) a ASGPR linker (e.g., a linker connecting the carbohydrate to the TREM).
  • exemplary ASGPR moieties include galactose (Gal), galactosamine (GalNH 2 ), or an N-acetylgalactosamine (GalNAc) moiety, for example, a Gal, GalNH 2 , or GalNAc, or an analog thereof.
  • the ASGPR binding moieties may comprise functional groups (e.g., hydroxyl groups, carboxylate groups, amines) that may be protected by a chemical protecting group, e.g., an acetyl group or methyl group.
  • the ASGPR binding moiety comprises a triantennary GalNAc moiety.
  • the ASGPR binding moiety may ASGPR binding moieties are described in further detail herein.
  • “Decreased expression,” as that term is used herein, refers to a decrease in comparison to a reference, e.g., in the case where altered control region, or addition of an agent, results in a decreased expression of the subject product, it is decreased relative to an otherwise similar cell without the alteration or addition.
  • a dihydrouridine hairpin domain refers to a domain which comprises sufficient RNA sequence to mediate, e.g., when present in an otherwise wildtype tRNA, recognition of aminoacyl-tRNA synthetase, e.g., acts as a recognition site for aminoacyl-tRNA synthetase for amino acid charging of the TREM.
  • a DHD mediates the stabilization of the TREM’s tertiary structure.
  • the DHD has at least 75, 80, 85, 85, 90, 95, or 100% identity with a naturally occurring DHD, e.g., a DHD encoded by a nucleic acid in Table 1.
  • the TREM can comprise a fragment or analog of a DHD, e.g., a DHD encoded by a nucleic acid in Table 1, which fragment in embodiments has DHD activity and in other embodiments does not have DHD activity.
  • the ASGPR binding moiety is present within the DHD.
  • the ASGPR binding moiety is bound to a nucleobase within a nucleotide in the DHD.
  • the DHD comprises positions 10-26 within the TREM sequence.
  • the ASGPR binding moiety is present within the DHD (e.g., positions 10-26) within the TREM sequence.
  • the DHD falls under the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the ASGPR binding moiety is present within the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or a sequence that differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the DHD comprises residues R 10 -R 11 -R 12 -R 13 -R 14 R 15 -R 16 -R 17 -R 18 - R 19 -R 20 -R 21 -R 22 -R 23 -R 24 -R 25 -R 26 -R 27 -R 28 of Formula I ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula I ZZZ refers to all species.
  • the DHD comprises residues R 10 -R 11 -R 12 -R 13 -R 14 R 15 -R 16 -R 17 -R 18 - R 19 -R 20 -R 21 -R 22 -R 23 -R 24 -R 25 -R 26 -R 27 -R 28 of Formula II ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula II ZZZ refers to mammals.
  • the DHD comprises residues R 10 -R 11 -R 12 -R 13 -R 14 R 15 -R 16 -R 17 -R 18 - R 19 -R 20 -R 21 -R 22 -R 23 -R 24 -R 25 -R 26 -R 27 -R 28 of Formula III ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula III ZZZ refers to humans.
  • ZZZ indicates any of the amino acids: Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamine, Glutamate, Glycine, Histidine, Isoleucine, Methionine, Leucine, Lysine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, or Valine.
  • exogenous nucleic acid refers to a nucleic acid sequence that is not present in or differs by at least one nucleotide from the closest sequence in a reference cell, e.g., a cell into which the exogenous nucleic acid is introduced.
  • an exogenous nucleic acid comprises a nucleic acid that encodes a TREM.
  • exogenous TREM refers to a TREM that:
  • (a) differs by at least one nucleotide or one post transcriptional modification from the closest sequence tRNA in a reference cell, e.g., a cell into which the exogenous nucleic acid is introduced;
  • (c) is present in a cell other than one in which it naturally occurs;
  • (d) has an expression profile, e.g., level or distribution, that is non-wildtype, e.g., it is expressed at a higher level than wildtype.
  • the expression profile can be mediated by a change introduced into a nucleic acid that modulates expression or by addition of an agent that modulates expression of the RNA molecule.
  • an exogenous TREM comprises 1, 2, 3 or 4 of properties (a)-(d).
  • GMP-grade composition refers to a composition in compliance with current good manufacturing practice (cGMP) guidelines, or other similar requirements.
  • cGMP current good manufacturing practice
  • a GMP-grade composition can be used as a pharmaceutical product.
  • the terms “increasing” and “decreasing” refer to modulating that results in, respectively, greater or lesser amounts of function, expression, or activity of a particular metric relative to a reference.
  • the amount of a marker of a metric e.g., protein translation, mRNA stability, protein folding
  • the amount of a marker of a metric may be increased or decreased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98%, 2X, 3X, 5X, 10X or more relative to the amount of the marker prior to administration or relative to the effect of a negative control agent.
  • the metric may be measured subsequent to administration at a time that the administration has had the recited effect, e.g., at least 12 hours, 24 hours, one week, one month, 3 months, or 6 months, after
  • “Increased expression,” as that term is used herein, refers to an increase in comparison to a reference, e.g., in the case where altered control region, or addition of an agent, results in an increased expression of the subject product, it is increased relative to an otherwise similar cell without the alteration or addition.
  • a Linker 2 region (L2) refers to a linker comprising residues R 8 -R 9 of a consensus sequence provided in the “Consensus Sequence” section.
  • a Linker 3 region (L3) that term is used herein, refers to a linker comprising residue R 29 of a consensus sequence provided in the “Consensus Sequence” section.
  • a “Linker 4 region (L4) refers to a domain comprising residue R 72 of a consensus sequence provided in the “Consensus Sequence” section.
  • the modification is present within the nucleobase, nucleotide sugar, or internucleotide linkage of a nucleotide of the TREM.
  • the modification can be naturally occurring or non-naturally occurring. In an embodiment, the modification is non-naturally occurring. In an embodiment, the modification is naturally occurring. In an embodiment, the modification is a synthetic modification. In an embodiment, the modification is a modification provided in Tables 5, 6, 7, 8 or 9.
  • a “naturally occurring nucleotide,” as that term is used herein, refers to a nucleotide that does not comprise a non-naturally occurring modification. In an embodiment, it includes a naturally occurring modification.
  • nucleotide refers to an entity comprising a sugar, typically a pentameric sugar; a nucleobase; and a phosphate linking group (e.g., internucleotide linkage).
  • a nucleotide comprises a naturally occurring, e.g., naturally occurring in a human cell, nucleotide, e.g., an adenine, thymine, guanine, cytosine, or uracil nucleotide.
  • the THD has at least 75, 80, 85, 85, 90, 95, or 100% identity with a naturally occurring THD, e.g., a THD encoded by a nucleic acid in Table 1.
  • the TREM can comprise a fragment or analog of a THD, e.g., a THD encoded by a nucleic acid in Table 1, which fragment in embodiments has THD activity and in other embodiments does not have THD activity.
  • the ASPGR binding moiety is present within the THD.
  • the ASGPR binding moiety is bound to a nucleobase within a nucleotide in the THD.
  • the THD comprises positions 50-64 within the TREM sequence.
  • the ASPGR binding moiety is present within the THD (e.g., positions 50-64) within the TREM sequence.
  • the THD falls under the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section or differs from the consensus sequence by no more than 1, 2, 5, or 10 positions.
  • the THD comprises residues -R 48 -R 49 -R 50 -R 51 -R 52 -R 53 -R 54 -R 55 -R 56 - R 57 -R 58 -R 59 -R 60 -R 61 -R 62 -R 63 -R 54 of Formula I ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula I ZZZ refers to all species.
  • the THD comprises residues -R 48 -R 49 -R 50 -R 51 -R 52 -R 53 -R 54 -R 55 -R 56 - R 57 -R 58 -R 59 -R 60 -R 61 -R 62 -R 63 -R 64 of Formula II ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula II ZZZ refers to mammals.
  • the THD comprises residues -R 48 -R 49 -R 50 -R 51 -R 52 -R 53 -R 54 -R 55 -R 56 - R 57 -R 58 -R 59 -R 60 -R 61 -R 62 -R 63 -R 64 of Formula II ZZZ , wherein ZZZ indicates any of the twenty amino acids.
  • Formula III ZZZ refers to humans.
  • ZZZ indicates any of the amino acids: Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamine, Glutamate, Glycine, Histidine, Isoleucine, Methionine, Leucine, Lysine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, or Valine.
  • the TREMs described in the present invention are synthetic molecules and are made, e.g., in a cell free reaction, e.g., in a solid state or liquid phase synthetic reaction. TREMs are chemically distinct, e.g., in terms of primary sequence, type or location of modifications from the endogenous tRNA molecules made in cells, e.g., in mammalian cells, e.g., in human cells.
  • a TREM can have a plurality (e.g., 2, 3, 4, 5, 6, 7, 8, 9) of the structures and functions of (a)-(v).
  • a TREM is non-native, as evaluated by structure or the way in which it was made.
  • a TREM comprises one or more of the following structures or properties:
  • an acceptor stem domain (a) an acceptor stem domain (an AStD), which typically comprises an ASt Domainl and an ASt Domain2;
  • VLD variable loop domain
  • THD thymine hairpin domain
  • a stem structure under physiological conditions, it comprises a stem structure and one or a plurality of loop structures, e.g., 1, 2, or 3 loops.
  • a loop can comprise a domain described herein, e.g., a domain selected from (a)-(e).
  • a loop can comprise one or a plurality of domains.
  • a stem or loop structure has at least 75, 80, 85, 85, 90, 95, or 100% identity with a naturally occurring stem or loop structure, e.g., a stem or loop structure encoded by a nucleic acid in Table 1.
  • the TREM can comprise a fragment or analog of a stem or loop structure, e.g., a stem or loop structure encoded by a nucleic acid in Table 1, which fragment in embodiments has activity of a stem or loop structure, and in other embodiments does not have activity of a stem or loop structure;
  • a tertiary structure e.g., an L-shaped tertiary structure
  • (h) adaptor function i.e., the TREM mediates acceptance of an amino acid, e.g., its cognate amino acid and transfer of the AA in the initiation or elongation of a polypeptide chain;
  • cognate adaptor function wherein the TREM mediates acceptance and incorporation of an amino acid (e.g., cognate amino acid) associated in nature with the anti-codon of the TREM to initiate or elongate a polypeptide chain;
  • an amino acid e.g., cognate amino acid
  • non-cognate adaptor function wherein the TREM mediates acceptance and incorporation of an amino acid (e.g., non-cognate amino acid) other than the amino acid associated in nature with the anti-codon of the TREM in the initiation or elongation of a polypeptide chain;
  • an amino acid e.g., non-cognate amino acid
  • a regulatory function e.g., an epigenetic function (e.g., gene silencing function or signaling pathway modulation function), cell fate modulation function, mRNA stability modulation function, protein stability modulation function, protein transduction modulation function, or protein compartmentalization function;
  • an epigenetic function e.g., gene silencing function or signaling pathway modulation function
  • cell fate modulation function e.g., mRNA stability modulation function, protein stability modulation function, protein transduction modulation function, or protein compartmentalization function
  • a post-transcriptional modification e.g., a naturally occurring post-transcriptional modification
  • a TREM comprises a full-length tRNA molecule or a fragment thereof.
  • a TREM comprises the following properties: (a)-(e).
  • a TREM comprises the following properties: (a) and (c).
  • a TREM comprises the following properties: (a), (c) and (h).
  • a TREM comprises the following properties: (a), (c), (h) and (b).
  • a TREM comprises the following properties: (a), (c), (h) and (e).
  • a TREM comprises the following properties: (a), (c), (h), (b) and (e).
  • a TREM comprises the following properties: (a), (c), (h), (b), (e) and (g).
  • a TREM comprises the following properties: (a), (c), (h) and (m).
  • a TREM comprises the following properties: (a), (c), (h), (m), and (g).
  • a TREM comprises the following properties: (a), (c), (h), (m) and (b).
  • a TREM comprises the following properties: (a), (c), (h), (m) and (e).
  • a TREM comprises the following properties: (a), (c), (h), (m), (g), (b) and (e).
  • a TREM comprises the following properties: (a), (c), (h), (m), (g), (b), (e) and (q).
  • a TREM comprises:
  • an amino acid attachment domain that binds an amino acid e.g., an AStD, as described in (a) herein;
  • the TREM comprises a flexible RNA linker which provides for covalent linkage of (i) to (ii).
  • the TREM mediates protein translation.
  • a TREM comprises a linker, e.g., an RNA linker, e.g., a flexible RNA linker, which provides for covalent linkage between a first and a second structure or domain.
  • an RNA linker comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 ribonucleotides.
  • a TREM can comprise one or a plurality of linkers, e.g, in embodiments a TREM comprising (a), (b), (c), (d) and (e) can have a first linker between a first and second domain, and a second linker between a third domain and another domain.
  • the TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2],
  • a TREM comprises an RNA sequence at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98 or 99% identical with, or which differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, 25, or 30 ribonucleotides from, an RNA sequence encoded by a DNA sequence listed in Table 1, or a fragment or functional fragment thereof.
  • a TREM comprises an RNA sequence encoded by a DNA sequence listed in Table 1, or a fragment or functional fragment thereof.
  • a TREM comprises an RNA sequence encoded by a DNA sequence at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98 or 99% identical with a DNA sequence listed in Table 1, or a fragment or functional fragment thereof.
  • a TREM comprises a TREM domain, e.g, a domain described herein, comprising at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical with, or which differs by no more than 1, 2, 3, 4, 5, 10, or 15, ribonucleotides from, an RNA encoded by a DNA sequence listed in Table 1, or a fragment or a functional fragment thereof.
  • a TREM comprises a TREM domain, e.g., a domain described herein, comprising an RNA sequence encoded by DNA sequence listed in Table 1, or a fragment or functional fragment thereof.
  • a TREM comprises a TREM domain, e.g., a domain described herein, comprising an RNA sequence encoded by DNA sequence at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98 or 99% identical with a DNA sequence listed in Table 1, or a fragment or functional fragment thereof.
  • a TREM is 76-90 nucleotides in length.
  • a TREM or a fragment or functional fragment thereof is between 10-90 nucleotides, between 10-80 nucleotides, between 10-70 nucleotides, between 10-60 nucleotides, between 10-50 nucleotides, between 10-40 nucleotides, between 10-30 nucleotides, between 10-20 nucleotides, between 20- 90 nucleotides, between 20-80 nucleotides, 20-70 nucleotides, between 20-60 nucleotides, between 20-50 nucleotides, between 20-40 nucleotides, between 30-90 nucleotides, between 30- 80 nucleotides, between 30-70 nucleotides, between 30-60 nucleotides, or between 30-50 nucleotides.
  • a TREM is aminoacylated, e.g., charged, with an amino acid by an aminoacyl tRNA synthetase.
  • a TREM is not charged with an amino acid, e.g., an uncharged TREM (uTREM).
  • uTREM uncharged TREM
  • a TREM comprises less than a full length tRNA.
  • a TREM can correspond to a naturally occurring fragment of a tRNA, or to a non-naturally occurring fragment.
  • Exemplary fragments include: TREM halves (e.g., from a cleavage in the ACHD, e.g., in the anticodon sequence, e.g., 5 ’halves or 3’ halves); a 5’ fragment (e.g., a fragment comprising the 5’ end, e.g., from a cleavage in a DHD or the ACHD); a 3’ fragment (e.g., a fragment comprising the 3’ end, e.g., from a cleavage in the THD); or an internal fragment (e.g., from a cleavage in one or more of the ACHD, DHD or THD).
  • TREM halves e.g., from a cleavage in the ACHD, e.g., in the
  • a “TREM fragment,” as used herein, refers to a portion of a TREM, wherein the TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]-[L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2],
  • non-cognate adaptor function TREM refers to a TREM which mediates initiation or elongation with an AA (a non-cognate AA) other than the AA associated in nature with the anti -codon of the TREM.
  • a non-cognate adaptor function TREM is also referred to as a mischarged TREM (mTREM).
  • a “non-naturally occurring sequence,” as that term is used herein, refers to a sequence wherein an Adenine is replaced by a residue other than an analog of adenine, a cytosine is replaced by a residue other than an analog of cytosine, a guanine is replaced by a residue other than an analog of guanine, and a uracil is replaced by a residue other than an analog of uracil.
  • An analog refers to any possible derivative of the ribonucleotides, A, G, C or U.
  • a sequence having a derivative of any one of ribonucleotides A, G, C or U is a non-naturally occurring sequence.
  • a “pharmaceutical TREM composition,” as that term is used herein, refers to a TREM composition that is suitable for pharmaceutical use.
  • a pharmaceutical TREM composition comprises a pharmaceutical excipient.
  • the TREM will be the only active ingredient in the pharmaceutical TREM composition.
  • the pharmaceutical TREM composition is free, substantially free, or has less than a pharmaceutically acceptable amount, of host cell proteins, DNA, e.g., host cell DNA, endotoxins, and bacteria.
  • the covalent modification occurs post-transcriptionally.
  • the covalent modification occurs co-transcriptionally.
  • the modification is made in vivo, e.g., in a cell used to produce a TREM.
  • the modification is made ex vivo, e.g., it is made on a TREM isolated or obtained from the cell which produced the TREM.
  • the post-transcriptional modification is selected from a post-transcriptional modification listed in Table 2.
  • a “subject,” as this term is used herein, includes any organism, such as a human or other animal.
  • the subject is a vertebrate animal (e.g., mammal, bird, fish, reptile, or amphibian).
  • the subject is a mammal, e.g., a human.
  • the method subject is a non-human mammal.
  • the subject is a non -human mammal such as a non-human primate (e.g., monkeys, apes), ungulate (e.g., cattle, buffalo, sheep, goat, pig, camel, llama, alpaca, deer, horses, donkeys), carnivore (e.g., dog, cat), rodent (e.g., rat, mouse), or lagomorph (e.g., rabbit).
  • a non-human primate e.g., monkeys, apes
  • ungulate e.g., cattle, buffalo, sheep, goat, pig, camel, llama, alpaca, deer, horses, donkeys
  • carnivore e.g., dog, cat
  • rodent e.g., rat, mouse
  • lagomorph e.g., rabbit
  • the subject is a bird, such as a member of the avian taxa Galliformes (e.g., chickens, turkeys, pheasants, quail), Anseriformes (e.g., ducks, geese), Paleaognathae (e.g., ostriches, emus), Columbiformes (e.g., pigeons, doves), or Psittaciformes (e.g., parrots).
  • avian taxa Galliformes e.g., chickens, turkeys, pheasants, quail
  • Anseriformes e.g., ducks, geese
  • Paleaognathae e.g., ostriches, emus
  • Columbiformes e.g., pigeons, doves
  • Psittaciformes e.g., par
  • the subject may be a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g, young adult, middle-aged adult, or senior adult)).
  • a non-human subject may be a transgenic animal.
  • a “synthetic TREM,” as that term is used herein, refers to a TREM which was synthesized other than in or by a cell having an endogenous nucleic acid encoding the TREM, e.g., a synthetic TREM is synthetized by cell-free solid phase synthesis.
  • a synthetic TREM can have the same, or a different, sequence, or tertiary structure, as a native tRNA.
  • a “recombinant TREM,” as that term is used herein, refers to a TREM that was expressed in a cell modified by human intervention, having a modification that mediates the production of the TREM, e.g., the cell comprises an exogenous sequence encoding the TREM, or a modification that mediates expression, e.g., transcriptional expression or post-transcriptional modification, of the TREM.
  • a recombinant TREM can have the same, or a different, sequence, set of post-transcriptional modifications, or tertiary structure, as a reference tRNA, e.g., a native tRNA.
  • tRNA refers to a naturally occurring transfer ribonucleic acid in its native state.
  • a “TREM composition,” as that term is used herein, refers to a composition comprising a plurality of TREMs, a plurality of TREM core fragments and/or a plurality of TREM fragments.
  • the TREM, TREM core fragment or TREM fragment has at least 70, 75, 80, 85, 90, or 95, or has 100%, identity with a sequence encoded by a nucleic acid in Table 1.
  • a TREM composition can comprise one or more species of TREMs, TREM core fragments or TREM fragments.
  • the TREM composition is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 95 or 99% dry weight TREMs (for a liquid composition dry weight refers to the weight after removal of substantially all liquid, e.g., after lyophilization).
  • the composition is a liquid.
  • the composition is dry, e.g., a lyophilized material.
  • the composition is a frozen composition.
  • the composition is sterile.
  • the composition comprises at least 0.5 g, 1.0 g, 5.0 g, 10 g, 15 g, 25 g, 50 g, 100 g, 200 g, 400 g, or 500 g (e.g., as determined by dry weight) of TREM.
  • at least X% of the TREMs in a TREM composition comprises a chemical modification at a selected position, and X is 80, 90, 95, 96, 97, 98, 99, or 99.5.
  • At least X% of the TREMs in a TREM composition comprises a chemical modification at a first position and a chemical modification at a second position, and X, independently, is 80, 90, 95, 96, 97, 98, 99, or 99.5.
  • the modification at the first and second position is the same.
  • the modification at the first and second position are different.
  • the nucleotide at the first and second position is the same, e.g., both are adenine.
  • the nucleotide at the first and second position are different, e.g., one is adenine and one is thymine.
  • At least X% of the TREMs in a TREM composition comprises a chemical modification at a first position and less than Y% have a chemical modification at a second position, wherein X is 80, 90, 95, 96, 97, 98, 99, or 99.5 and Y is 20, 20, 5, 2, 1, .1, or .01.
  • the nucleotide at the first and second position is the same, e.g., both are adenine.
  • the nucleotide at the first and second position are different, e.g., one is adenine and one is thymine.
  • a “variable loop domain (VLD),” as that term is used herein refers to a domain which comprises sufficient RNA sequence to mediate, e.g., when present in an otherwise wildtype tRNA, recognition of aminoacyl-tRNA synthetase, e.g., acts as a recognition site for aminoacyl - tRNA synthetase for amino acid charging of the TREM.
  • a VLD mediates the stabilization of the TREM’s tertiary structure.
  • a VLD modulates, e.g., increases, the specificity of the TREM, e.g., for its cognate amino acid, e.g., the VLD modulates the TREM’s cognate adaptor function.
  • the VLD has at least 75, 80, 85, 85, 90, 95, or 100% identity with a naturally occurring VLD, e.g., a VLD encoded by a nucleic acid in Table 1.
  • the TREM can comprise a fragment or analog of a VLD, e.g., a VLD encoded by a nucleic acid in Table 1, which fragment in embodiments has VLD activity and in other embodiments does not have VLD activity.
  • the ASGPR binding moiety is present within the VLD. In an embodiment, the ASGPR binding moiety is bound to a nucleobase within a nucleotide in the VLD.
  • the VLD comprises positions 44-49 within the TREM sequence.
  • the ASGPR binding moiety is present within the VLD (e.g., positions 44-49) within the TREM sequence.
  • the VLD falls under the corresponding sequence of a consensus sequence provided in the “Consensus Sequence” section.
  • TREM entities e.g., a TREM, a TREM Core Fragment, or a TREM Fragment, modified with an asialoglycoprotein receptor (ASGPR) binding moiety
  • a TREM entity e.g., a TREM
  • the ASGPR binding moiety may be conjugated to a nucleobase within the TREM entity, or within an intemucleotide linkage of the TREM entity, or at a terminus (e.g., the 5’ or 3’ terminus) of the TREM entity.
  • a TREM entity e.g., a TREM
  • a TREM entity includes a TREM comprising a sequence of Formula A; a TREM core fragment comprising a sequence of Formula B; or a TREM fragment comprising a portion of a TREM which TREM comprises a sequence of Formula A.
  • a TREM comprises a sequence of Formula A: [L 1 ]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is present within the ASt Domainl (e.g., on a nucleobase, at a terminus (e.g., the 5’ terminus), or within the intemucleotide linkage of ASt Domainl). In an embodiment, the ASGPR binding moiety is present on a nucleobase of a nucleotide within ASt Domainl.
  • the ASGPR binding moiety is present at the 5’ terminus within ASt Domainl or at [LI], In an embodiment, the ASGPR binding moiety is present within an internucleotide linkage of ASt Domainl. In an embodiment, [VL Domain] is optional. In an embodiment, [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is present within the ASt Domain2 (e.g., on a nucleobase, at a terminus (e.g., 3’ terminus), or within the intemucleotide linkage of ASt Domain2).
  • the ASGPR binding moiety is present on a nucleobase of a nucleotide within ASt Domain2.
  • the ASGPR binding moiety is present at the 3’ terminus within ASt Domain2.
  • the ASGPR binding moiety is present within an intemucleotide linkage of ASt Domain2.
  • [VL Domain] is optional.
  • [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is present within either one or both of ASt Domainl and ASt Domain2 (e.g., on a nucleobase, at a terminus (e.g., 5’ or 3’ terminus), or within the internucleotide linkage of ASt Domainl or ASt Domain2).
  • the ASGPR binding moiety is present on a nucleobase of a nucleotide within ASt Domainl or ASt Domain2.
  • the ASGPR binding moiety is present at the 5’ terminus within ASt Domainl or [LI] or the 3’ terminus within ASt Domain2. In an embodiment, the ASGPR binding moiety is present within an internucleotide linkage of ASt Domainl or ASt Domain2. In an embodiment, [VL Domain] is optional. In an embodiment, [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is present within the DH Domain (e.g., on a nucleobase or within the internucleotide linkage of the DH Domain). In an embodiment, the ASGPR binding moiety is present on a nucleobase of a nucleotide within the DH Domain. In an embodiment, the ASGPR binding moiety is present within an intemucleotide linkage of the DH Domain. In an embodiment, [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is within the ACH Domain (e.g., on a nucleobase or within the intemucleotide linkage of the ACH Domain). In an embodiment, the ASGPR binding moiety is present on a nucleobase of a nucleotide within the ACH Domain. In an embodiment, the ASGPR binding moiety is present within an intemucleotide linkage of the ACH Domain. In an embodiment, [VL Domain] is optional. In an embodiment, [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is present within the VL Domain (e.g., on a nucleobase or within the internucleotide linkage of the VL Domain). In an embodiment, the ASGPR binding moiety is present on a nucleobase of a nucleotide within the VL Domain. In an embodiment, the ASGPR binding moiety is present within an intemucleotide linkage of the VL Domain. In an embodiment, [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is present within the TH Domain (e.g., on a nucleobase or within the intemucleotide linkage of the TH Domain). In an embodiment, the ASGPR binding moiety is present on a nucleobase of a nucleotide within the TH Domain. In an embodiment, the ASGPR binding moiety is present within an intemucleotide linkage of the TH Domain. In an embodiment, [VL Domain] is optional. In an embodiment, [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is bound to a nucleobase within one or more domains selected from [ASt Domainl], [DH Domain], [ACH Domain], [TH Domain], and/or [ASt Domain2],
  • [VL Domain] is optional.
  • [LI] is optional.
  • a TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]- [L2]-[DH Domain]-[L3]-[ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], wherein the ASGPR binding moiety is bound to an intemucleotide linkage within one or more domains selected from [ASt Domainl], [DH Domain], [ACH Domain], [TH Domain], and/or [ASt Domain2],
  • [VL Domain] is optional.
  • [LI] is optional.
  • a TREM fragment comprises a portion of a TREM, wherein the TREM comprises a sequence of Formula A: [Ll]-[ASt Domainl]-[L2]-[DH Domain]-[L3]- [ACH Domain] -[VL Domain]-[TH Domain]-[L4]-[ASt Domain2], and wherein the TREM fragment comprises: one, two, three or all or any combination of the following: a TREM half (e.g., from a cleavage in the ACH Domain, e.g., in the anticodon sequence, e.g., a 5 ’half or a 3’ half); a 5’ fragment (e.g., a fragment comprising the 5’ end, e.g., from a cleavage in a DH Domain or the ACH Domain); a 3’ fragment (e.g., a fragment comprising the 3’ end, e.g., from a cleavage in the TH Domain); or an internal
  • Exemplary TREM fragments include TREM halves (e.g., from a cleavage in the ACHD, e.g., 5 ’TREM halves or 3’ TREM halves), a 5’ fragment (e.g., a fragment comprising the 5’ end, e.g., from a cleavage in a DHD or the ACHD), a 3’ fragment (e.g., a fragment comprising the 3’ end of a TREM, e.g., from a cleavage in the THD), or an internal fragment (e.g., from a cleavage in one or more of the ACHD, DHD or THD).
  • TREM halves e.g., from a cleavage in the ACHD, e.g., 5 ’TREM halves or 3’ TREM halves
  • a 5’ fragment e.g., a fragment comprising the 5’ end, e.g., from a cleavage in a D
  • a TREM, a TREM core fragment or a TREM fragment can be charged with an amino acid (e.g., a cognate amino acid); charged with a non-cognate amino acid (e.g., a mischarged TREM (mTREM)); or not charged with an amino acid (e.g., an uncharged TREM (uTREM)).
  • an amino acid e.g., a cognate amino acid
  • mTREM mischarged TREM
  • uTREM uncharged TREM
  • a TREM, a TREM core fragment or a TREM fragment can be charged with an amino acid selected from alanine, arginine, asparagine, aspartate, cysteine, glutamine, glutamate, glycine, histidine, isoleucine, methionine, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
  • an amino acid selected from alanine, arginine, asparagine, aspartate, cysteine, glutamine, glutamate, glycine, histidine, isoleucine, methionine, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
  • the TREM, TREM core fragment or TREM fragment is a cognate TREM. In an embodiment, the TREM, TREM core fragment or TREM fragment is a noncognate TREM. In an embodiment, the TREM, TREM core fragment or TREM fragment recognizes a codon provided in Table 2 or Table 3.
  • a TREM comprises a ribonucleic acid (RNA) sequence encoded by a deoxyribonucleic acid (DNA) sequence disclosed in Table 1, e.g., any one of SEQ ID NOs: 1- 451 disclosed in Table 1.
  • a TREM comprises an RNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM comprises an RNA sequence encoded by a DNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM, a TREM core fragment, or TREM fragment comprises at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence encoded by a DNA sequence disclosed in Table 1, e.g., at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence encoded by any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM, a TREM core fragment, or TREM fragment comprises at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM, a TREM core fragment, or TREM fragment comprises at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence encoded by a DNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of an RNA sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of an RNA sequence encoded by a DNA sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence encoded by a DNA sequence disclosed in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence encoded by a DNA sequence with at least 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, 99% or 100% identity to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • a TREM core fragment or a TREM fragment comprises a sequence of a length of between 10-90 ribonucleotides (mt), between 10-80 rnt, between 10-70 mt, between 10-60 rnt, between 10-50 rnt, between 10-40 mt, between 10-30 mt, between 10-20 rnt, between 20-90 rnt, between 20-80 rnt, 20-70 mt, between 20-60 mt, between 20-50 rnt, between 20-40 rnt, between 30-90 mt, between 30-80 mt, between 30-70 mt, between 30-60 rnt, or between 30- 50 mt.
  • mt 10-90 ribonucleotides
  • the TREM described herein comprises a consensus sequence of Formula I ZZZ ,
  • the TREM described herein comprises a consensus sequence of Formula II ZZZ ,
  • the TREM described herein comprises a consensus sequence of Formula IIII ZZZ ,
  • the present disclosure features a TREM comprising an asialoglycoprotein receptor (ASGPR) binding moiety.
  • the ASGPR is a C-type lectin primarily expressed on the sinusoidal surface of hepatocytes, and comprises a major (48 kDa, ASGPR-1) and a minor (40 kDa, ASGPR-2) subunit.
  • the ASGPR is involved in the binding, internalization, and subsequent clearance of glycoproteins containing an N-terminal galactose (Gal) or N-terminal N- acetylgalactosamine (GalNAc) residues from circulation, such as antibodies.
  • Gal N-terminal galactose
  • GalNAc N-terminal N- acetylgalactosamine
  • ASGPRs have also been shown to be involved in the clearance of low density lipoprotein, fibronection, and certain immune cells, and may be utilized by certain viruses for hepatocyte entry (see, e.g., Yang J., et al (2006) J Viral Hepat 13: 158-165 and Guy, CS et al (2011) Nat Rev Immunol 8:874-887).
  • the ASGPR binding moiety as described herein may refer to structure comprising: (i) a ASGPR carbohydrate and (ii) an ASGPR linker (e.g., a linker connecting the carbohydrate to the TREM).
  • ASGPR linker e.g., a linker connecting the carbohydrate to the TREM.
  • carbohydrate refers to compound comprising one or more monosaccharide moieties comprising at least 3 carbon atoms (e.g., arranged in a linear, branched, or cyclic structure) and an oxygen, nitrogen, or sulfur atom, or a fragment or variant of a monosaccharide moiety comprising at least 3 carbon atoms (e.g., arranged in a linear, branched, or cyclic structure) and an oxygen, nitrogen, or sulfur atom.
  • Each monosaccharide moiety or fragment or variant thereof may be a tetrose, pentose, hexose, or heptose. Each monosaccharide moiety or fragment or variant thereof may exist as an aldose, ketose, sugar alcohol, and, where appropriate, in the L or D form. Exemplary monosaccharide moieties may be amino sugars, N- acetylamino sugars, imino sugars, deoxysugars, or sugar acids.
  • Carbohydrates may comprise individual monosaccharide moieties, or may further comprise a disaccharide, oligosaccharide (e.g., a tri saccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, octasaccharide), a polysaccharide, or combinations thereof.
  • oligosaccharide e.g., a tri saccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, octasaccharide
  • a polysaccharide or combinations thereof.
  • Exemplary carbohydrates include ribose, arabinose, lyxose, xylose, deoxyribose, ribulose, xylulose, glucose, galactose, mannose, gulose, idose, talose, allose, altrose, psicose, fructose, sorbose, tagatose, rhamnose, pneumose, quinovose, fucose, mannuheptulose, sedoheptulose, galactosamine, mannosamine, glucosamine, N-acetylglucosamine, N-acetylgalactosamine, N-acetylmannosamine, glucuronic acid, galacturonic acid, mannuronic acid, guluronic acid, iduronic acid, tagaturonic acid, frucuronic acid, galactosaminuronic acid, mannosaminuronic acid, glucosaminuronic acid, N
  • the carbohydrate may comprise one or more monosaccharide moieties linked by a glycosidic bond.
  • the glycosidic bond comprises a l->2 glycosidic bond, a l->3 glycosidic bond, a l->4 glycosidic bond, or a l->6 glycosidic bond.
  • each glycosidic bonds may be present in the alpha or beta configuration.
  • the one or more monosaccharide moieties are linked directly by a glycosidic bond or are separated by a linker.
  • the ASGPR binding moiety comprises a galactose (Gal), galactosamine (GalNH 2 ), or an N-acetylgalactosamine (GalNAc) moiety, for example, a Gal, GalNH 2 , or GalNAc, or an analog thereof.
  • the ASGPR binding moiety comprises a GalNAc moiety (e.g., GalNAc).
  • the ASGPR binding moiety comprises a plurality of GalNAc moieties (e.g., GalNAcs), e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more GalNAc moieties (e.g., GalNAcs).
  • the ASGPR binding moiety comprises between 2 and 20 GalNAcs moieties (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 GalNAc moieties). In an embodiment, the ASGPR binding moiety comprises between 2 and 10 GalNAc moieties (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 GalNAc moieties). In an embodiment, the ASGPR binding moiety comprises between 2 and 5 GalNAc moieties (e.g., 2, 3, 4, or 5 GalNAc moieties). In an embodiment, the ASGPR binding moiety comprises 2 GalNAc moieties. In an embodiment, the ASGPR binding moiety comprises 3 GalNAc moieties. In an embodiment, the ASGPR binding moiety comprises 4 GalNAc moieties. In an embodiment, the ASGPR moieties comprises 5 GalNAc moieties.
  • the GalNAc moiety comprises a structure of Formula (I): salt thereof, wherein each of X and Y is independently O,
  • each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, C(O)-alkyl, C(O)-alkenyl, C(O)-alkynyl, C(O)-heteroalkyl, C(O)-haloalkyl, C(O)-aryl, C(O)-heteroaryl, C(O)-cycloalkyl, or C(O)-heterocyclyl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more R 8 ; or R 3 and R 4 are taken together with the oxygen atoms to which they are
  • X is O. In some embodiments, Y is O. In some embodiments, each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen or alkyl (e.g., CFF). In some embodiments, R 2a is hydrogen. In some embodiments, R 2b is C(O)CH 3 . In some embodiments, each of R 6a and R 6b is hydrogen. In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1. In some embodiments, the GalNAc moiety is connected to a linker or TREM at R 2a . In some embodiments, the GalNAc moiety is connected to a linker or TREM at R 2b .
  • the GalNAc moiety is connected to a linker or TREM at R 3 . In some embodiments, the GalNAc moiety is connected to a linker or TREM at R 4 . In some embodiments, the GalNAc moiety is connected to a linker or TREM at R 5 . In some embodiments, the GalNAc moiety is connected to a linker or TREM at R 6a or R 6b . In some embodiments, the GalNAc moiety is connected to a linker or TREM at a plurality of positions, e.g., at least two of R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , R 6a , and R 6b .
  • the GalNAc moiety is comprises a structure of Formula (La) thereof, wherein R 2a is hydrogen or alkyl; R 2b is - C(O)alkyl (e.g., C(O)CH 3 ); each of R 3 , R 4 , and R 5 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, C(O)-alkyl, C(O)- alkenyl, C(O)-alkynyl, C(O)-heteroalkyl, C(O)-haloalkyl, C(O)-aryl, C(O)-heteroaryl, C(O)- cycloalkyl, or C(O)-heterocyclyl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, ary
  • each of R 3 , R 4 , and R 5 are independently hydrogen or alkyl (e.g., CH 3 ).
  • R 2a is hydrogen.
  • R 2b is C(O)CH 3 .
  • the GalNAc moiety comprises a structure of Formula (II): salt thereof, wherein X is O, N(R 7 ), or S; each of W or
  • Y is independently O or C(R 10a )(R 10b ), wherein one of W and Y is O; each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, C(O)-alkyl, C(O)-alkenyl, C(O)-alkynyl, C(O)-heteroalkyl, C(O)- haloalkyl, C(O)-aryl, C(O)-heteroaryl, C(O)-cycloalkyl, or C(O)-heterocyclyl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more
  • the GalNAc moiety comprises a structure of Formula (II-a): salt thereof, wherein X is O, N(R 7 ), or S; each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, C(O)-alkyl, C(O)-alkenyl, C(O)-alkynyl, C(O)-heteroalkyl, C(O)-haloalkyl, C(O)-aryl, C(O)-heteroaryl, C(O)-cycloalkyl, or C(O)-heterocyclyl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl, where
  • the GalNAc moiety comprises a structure of Formula (Il-b): salt thereof, wherein X is O, N(R 7 ), or S; each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, C(O)-alkyl, C(O)-alkenyl, C(O)-alkynyl, C(O)-heteroalkyl, C(O)-haloalkyl, C(O)-aryl, C(O)-heteroaryl, C(O)-cycloalkyl, or C(O)-heterocyclyl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl, where
  • the ASGPR binding moiety comprises a structure of Formula (III): salt thereof, wherein each of R 1 , R 2a , R 2b ,
  • R 3 , R 4 , R 5 , R 6a , and R 6b and subvariables thereof are as defined for Formula (I), L is a linker, and n is an integer between 1 and 100, wherein represents an attachment point to a branching point, additional linker, or TREM, e.g., a linker, a nucleobase, intemucleotide linkage, or terminus within the TREM sequence.
  • TREM e.g., a linker, a nucleobase, intemucleotide linkage, or terminus within the TREM sequence.
  • X is O.
  • each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen or alkyl (e.g., CH 3 ).
  • R 2a is hydrogen.
  • R 2b is C(O)CH 3 .
  • each of R 6a and R 6b is hydrogen.
  • n is an integer between 1 and 50.
  • n is an integer between 1 and 25.
  • n is an integer between 1 and 10.
  • n is an integer between 1 and 5.
  • n is 1, 2, 3, 4, or 5.
  • n is 1.
  • L comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, L comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, L is cleavable or non- cleavable.
  • linker refers to an organic moiety that connects two or more parts of a compound, e.g., through a covalent bond.
  • a linker may linear or branched.
  • a linker comprises a heteroatom, such as a nitrogen, sulfur, oxygen, phosphorus, silicon, or boron atom.
  • the linker comprises a cyclic group (e.g., an aryl, heteroaryl, cycloalkyl, or heterocyclyl group).
  • a linker comprises a functional group such as an amide, ketone, ester, ether, thioester, thioether, thiol, hydroxyl, amine, cyano, nitro, azide, triazole, pyrroline, p-nitrophenyl, alkene, or alkyne group. Any atom within a linker may be substituted or unsubstituted.
  • a linker comprises an arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkyl
  • a linker comprises a polyethylene glycol group (e.g., PEG1, PEG2, PEG3, PEG4, PEG5, PEG6, PEG7, PEG8, PEG10, PEG12, PEG14, PEG16, PEG18, PEG20, PEG24, PEG28, PEG32, PEG100, PEG200, PEG250, PEG500, PEG600, PEG700, PEG750, PEG800, PEG900, PEG1000, PEG2000, or PEG3000).
  • L comprises a PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 group.
  • L comprises a plurality of PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups (e g., 2, 3, 4, or 5 PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups).
  • L comprises a PEG2 group.
  • L comprises a plurality of PEG2 groups.
  • L comprises a PEG3 group.
  • L comprises a plurality of PEG3 groups.
  • L comprises a PEG4 group.
  • L comprises a plurality of PEG4 groups.
  • the linker comprises between 1 and 1000 atoms (e.g., between 1 and 750 atoms, 1 and 500 atoms, 1 and 250 atoms, 1 and 100 atoms, 1 and 75 atoms, 1 and 50 atoms, 1 and 25 atoms, and 1 and 10 atoms). In some embodiments, the linker comprises between 1 and 100 atoms. In some embodiments, the linker comprises between 1 and 50 atoms. In some embodiments, the linker comprises between 1 and 25 atoms.
  • the linker is linear and comprises between 1 and 1000 atoms (e.g., between 1 and 750 atoms, 1 and 500 atoms, 1 and 250 atoms, 1 and 100 atoms, 1 and 75 atoms, 1 and 50 atoms, 1 and 25 atoms, and 1 and 10 atoms). In some embodiments, the linker is linear and comprises between 1 and 100 atoms. In some embodiments, the linker is linear and comprises between 1 and 50 atoms. In some embodiments, the linker is linear and comprises between 1 and 25 atoms.
  • the linker is branched, and each branch comprises between 1 and 1000 atoms (e.g., between 1 and 750 atoms, 1 and 500 atoms, 1 and 250 atoms, 1 and 100 atoms, 1 and 75 atoms, 1 and 50 atoms, 1 and 25 atoms, and 1 and 10 atoms). In some embodiments, the linker is branched, and each branch comprises between 1 and 100 atoms. In some embodiments, the linker is branched, and each branch comprises between 1 and 50 atoms. In some embodiments, the linker is branched, and each branch comprises between 1 and 25 atoms.
  • the ASGPR binding moiety comprises a structure of Formula (III- a):
  • each of R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , R 6a , and R 6b and subvariables thereof are as defined for Formula (I), each of L 1 and L 2 is independently a linker, each of m and n is independently an integer between
  • M is a linker, wherein represents an attachment point to a branching point, additional linker, or TREM, e.g., a linker, a nucleobase, internucleotide linkage, or terminus within the TREM sequence.
  • X is O (e.g., X in each of A and B is O).
  • each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen or alkyl (e.g., CH 3 ) (e.g., R 1 , R 3 , R 4 , and R 5 in each of A and B is independently hydrogen or alkyl).
  • R 2a is hydrogen (e.g., R 2a in each of A and B is hydrogen).
  • R 2b is C(O)CH 3 (e.g., R 2b in each of A and B is C(O)CH 3 ).
  • each of R 6a and R 6b is hydrogen (e.g., R 6a and R 6b in each of A and B is hydrogen).
  • each of m and n is independently an integer between 1 and 50.
  • each of m and n is independently an integer between 1 and 25.
  • each of m and n is independently an integer between 1 and 10.
  • each of m and n is independently an integer between 1 and 5.
  • each of m and n is independently 1, 2, 3, 4, or 5.
  • each of m and n is independently 1.
  • each of L 1 and L 2 independently comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, each of L 1 and L 2 independently comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, each of L 1 and L 2 independently is cleavable or non- cleavable.
  • each of L 1 and L 2 independently comprises a polyethylene glycol group (e g., PEG1, PEG2, PEG3, PEG4, PEG5, PEG6, PEG7, PEG8, PEG10, PEG12, PEG14, PEG16, PEG18, PEG20, PEG24, PEG28, PEG32, PEG100, PEG200, PEG250, PEG500, PEG600, PEG700, PEG750, PEG800, PEG900, PEG1000, PEG2000, or PEG3000).
  • a polyethylene glycol group e g., PEG1, PEG2, PEG3, PEG4, PEG5, PEG6, PEG7, PEG8, PEG10, PEG12, PEG14, PEG16, PEG18, PEG20, PEG24, PEG28, PEG32, PEG100, PEG200, PEG250, PEG500, PEG600, PEG700, PEG750, PEG800, PEG900, PEG1000, PEG2000, or
  • each of L 1 and L 2 independently comprises a PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 group. In some embodiments, each of L 1 and L 2 independently comprises a plurality of PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups (e g., 2, 3, 4, or 5 PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups). In some embodiments, each of L 1 and L 2 independently comprises a PEG2 group. In some embodiments, each of L 1 and L 2 independently comprises a plurality of PEG2 groups. In some embodiments, each of L 1 and L 2 independently comprises a PEG3 group.
  • each of L 1 and L 2 independently comprises a plurality of PEG3 groups. In some embodiments, each of L 1 and L 2 independently comprises a PEG4 group. In some embodiments, each of L 1 and L 2 independently comprises a plurality of PEG4 groups.
  • M comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, M comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, M is cleavable or non-cleavable.
  • the ASGPR binding moiety comprises a structure of Formula (III- b):
  • R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , R 6a , and R 6b and subvariables thereof are as defined for Formula (I), each of L 1 , L 2 , and L 3 is independently a linker, each of m, n, and o is independently an integer between 1 and 100, and M is a linker, wherein represents an attachment point to a branching point, additional linker, or TREM, e.g., a linker, a nucleobase, intemucleotide linkage, or terminus within the TREM sequence.
  • TREM e.g., a linker, a nucleobase, intemucleotide linkage, or terminus within the TREM sequence.
  • X is O (e.g., X in each of A, B, and C is O).
  • each of R 1 , R 3 , R 4 , and R 5 are independently hydrogen or alkyl (e.g., CH 3 ) (e.g., R 1 , R 3 , R 4 , and R 5 in each of A, B, and C is independently hydrogen or alkyl).
  • R 2a is hydrogen (e.g., R 2a in each of A, B, and C is hydrogen).
  • R 2b is C(O)CH 3 (e.g., R 2b in each of A, B, and C is C(O)CH 3 ).
  • each of R 6a and R 6b is hydrogen (e.g., R 6a and R 6b in each of A, B, and C is hydrogen).
  • each of m, n, and o is independently an integer between 1 and 50.
  • each of m, n, and o is independently an integer between 1 and 25.
  • each of m, n, and o is independently an integer between 1 and 10.
  • each of m, n, and o is independently an integer between 1 and 5.
  • each of m, n, and o is independently 1, 2, 3, 4, or 5.
  • each of m, n, and o is independently 1.
  • each of L 1 , L 2 , and L 3 independently comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, each of L 1 , L 2 , and L 3 independently comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, each of L 1 , L 2 , and L 3 independently is cleavable or non-cleavable. In an embodiment, each of L 1 and L 2 independently is cleavable or non-cleavable.
  • each of L 1 , L 2 , and L 3 independently comprises a polyethylene glycol group (e g., PEG1, PEG2, PEG3, PEG4, PEG5, PEG6, PEG7, PEG8, PEG10, PEG12, PEG14, PEG16, PEG18, PEG20, PEG24, PEG28, PEG32, PEG100, PEG200, PEG250, PEG500, PEG600, PEG700, PEG750, PEG800, PEG900, PEG1000, PEG2000, or PEG3000).
  • each of L 1 , L 2 , and L 3 independently comprises a PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups (e.g., 2, 3, 4, or 5 PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups).
  • each of L 1 , L 2 , and L 3 independently comprises a PEG2 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG2 groups.
  • each of L 1 , L 2 , and L 3 independently comprises a PEG3 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG3 groups.
  • each of L 1 , L 2 , and L 3 independently comprises a PEG4 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG4 groups.
  • M comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, M comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, M is cleavable or non-cleavable.
  • the ASGPR binding moiety comprises a structure of Formula (III- c):
  • R 5 and subvariables thereof are as defined for Formula (I), each of L 1 , L 2 , and L 3 is independently a linker, and M is a linker, wherein represents an attachment point to a branching point, additional linker, or TREM, e.g., a linker, a nucleobase, internucleotide linkage, or terminus within the TREM sequence.
  • TREM e.g., a linker, a nucleobase, internucleotide linkage, or terminus within the TREM sequence.
  • each of R 3 , R 4 , and R 5 are independently hydrogen or alkyl (e.g., CH 3 ).
  • R 2a is hydrogen.
  • R 2b is C(O)CH 3 .
  • each of L 1 , L 2 , and L 3 independently comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, each of L 1 , L 2 , and L 3 independently comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, each of L 1 , L 2 , and L 3 independently is cleavable or non-cleavable. In an embodiment, each of L 1 and L 2 independently is cleavable or non-cleavable.
  • each of L 1 , L 2 , and L 3 independently comprises a polyethylene glycol group (e.g, PEG1, PEG2, PEG3, PEG4, PEG5, PEG6, PEG7, PEG8, PEG10, PEG12, PEG14, PEG16, PEG18, PEG20, PEG24, PEG28, PEG32, PEG100, PEG200, PEG250, PEG500, PEG600, PEG700, PEG750, PEG800, PEG900, PEG1000, PEG2000, or PEG3000).
  • each of L 1 , L 2 , and L 3 independently comprises a PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups (e.g., 2, 3, 4, or 5 PEG1, PEG2, PEG3, PEG4, PEG5, or PEG6 groups).
  • each of L 1 , L 2 , and L 3 independently comprises a PEG2 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG2 groups.
  • each of L 1 , L 2 , and L 3 independently comprises a PEG3 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG3 groups.
  • each of L 1 , L 2 , and L 3 independently comprises a PEG4 group.
  • each of L 1 , L 2 , and L 3 independently comprises a plurality of PEG4 groups.
  • M comprises an alkylene, alkenylene, alkynylene, heteroalkylene, or haloalkylene group. In an embodiment, M comprises an ester, amide, disulfide, ether, carbonate, aryl, heteroaryl, cycloalkyl, or heterocyclyl group. In an embodiment, M is cleavable or non-cleavable.
  • the ASGPR binding moiety comprises a compound selected from:
  • the ASGPR binding moiety is a compound (X-i). In some embodiments, the ASGPR binding moiety is compound (X-ii). In some embodiments, the ASGPR binding moiety is compound (X-iii). In some embodiments, the ASGPR binding moiety is compound (X-iv). In some embodiments, the ASGPR binding moiety is compound (X-v). In some embodiments, the ASGPR binding moiety is compound (X-vi). In some embodiments, the ASGPR binding moiety is compound (X-vii). In some embodiments, the ASGPR binding moiety is compound (X-viii). In some embodiments, the ASGPR binding moiety is compound (X-ix).
  • the ASGPR binding moiety is compound (X-x). In some embodiments, the ASGPR binding moiety is compound (X-xi). In some embodiments, the ASGPR binding moiety is compound (X-xii). In some embodiments, the ASGPR binding moiety is compound (X-xiii). In some embodiments, the ASGPR binding moiety is compound (X-xiv). In some embodiments, the ASGPR binding moiety is compound (X-xv). In some embodiments, the ASGPR binding moiety is compound (X-xvi). In some embodiments, the ASGPR binding moiety is compound (X-xvii). In some embodiments, the ASGPR binding moiety is compound (X-xviii).
  • the ASGPR binding moiety is compound (X-xix). In some embodiments, the ASGPR binding moiety is compound (X-xx). In some embodiments, the ASGPR binding moiety is compound (X-xxi). In some embodiments, the ASGPR binding moiety is compound (X-xxii). In some embodiments, the ASGPR binding moiety is compound (X-xxiii). In some embodiments, the ASGPR binding moiety is a compound selected from compound (X-i), (X- xxii), and (X-xxii).
  • the ASGPR binding moiety comprises a linker comprising a cyclic moiety, such as a pyrroline ring.
  • the ASGPR binding moiety comprises a structure of Formula (CII):
  • R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 are each independently for each occurrence H, — CH 2 OR 3 , or OR b ;
  • R a and R b are each independently for each occurrence hydrogen, a hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethyleneglycol (PEG), a phosphate, a diphosphate, a triphosphate, a phosphonate, a phosphonothioate, a phosphonodi thioate, a phosphorothioate, a phosphorothiolate, a phosphorodithioate
  • the compound of Formula (CII) is selected from:
  • the ASGPR binding moiety is a compound or substructure disclosed in U.S. Patent No. 8,106,022, which is incorporated herein by reference in its entirety.
  • the ASGPR binding moiety is a compound (CII-i). In some embodiments, the ASGPR binding moiety is a compound (Cll-ii). In some embodiments, the ASGPR binding moiety is a compound (Cll-iii). In some embodiments, the ASGPR binding moiety is a compound (CII-iv). In some embodiments, the ASGPR binding moiety is a compound (CII-v). In some embodiments, the ASGPR binding moiety is a compound (Cll-vi).
  • the ASGPR binding moiety is a compound of Formula (C-1), (C- 2),(C-3) or (C4):
  • the ASGPR binding moiety is a compound (C-1). In some embodiments, the ASGPR binding moiety is a compound (C-2). In some embodiments, the ASGPR binding moiety is a compound (C-3). In some embodiments, the ASGPR binding moiety is a compound (C-4).
  • the compound of Formula (C-1), (C-2), (C-3) or (C4) comprises: wherein n’ is 1 or 2 or a pharmaceutically acceptable salt thereof.
  • the ASGPR binding moiety is a compound of Formula (E): or a pharmaceutically acceptable salt thereof, wherein: n is i, 2 or 3; W is absent or is a peptide; L is -(T-Q-T-Q)m-, wherein each T is independently absent or is (C 1 -C 10 ) alkylene, (C 2 - C 10 ) alkenylene, or (C 2 -C 10 ) alkynylene, wherein one or more carbon groups of said T may each independently be replaced with a heteroatom group independently selected from -O-, -S-, and - N(R 4 )- wherein the heteroatom groups are separated by at least 2 carbon atoms, wherein said alkylene, alkenylene, alkynylene, may each independently be substituted by one or more halo atoms; each Q is independently absent or is C(O), C(O)- R 4 , R 4 -C(O), O-C(O)- R
  • the compound of Formula (E) is selected from:
  • n is 1. In some embodiments, n is 2. In some embodiments, n is 3.
  • the compound is:
  • the ASGPR binding moiety is a compound or substructure disclosed in WO2017/083368, which is incorporated herein by reference in its entirety.
  • the ASGPR binding moiety is selected from: ⁇ wherein one of X or Y is a branching point, a linker, or a TREM, e.g., a linker, a nucleobase, internucleotide linkage, or terminus within the TREM sequence, and the other of X and Y is hydrogen.
  • the ASGPR binding moiety comprises a structure of Formula (Xll-a):
  • the ASGPR binding moiety is a compound or substructure disclosed in Nucleic Acids (2016) 5:e317 or WO2015/042447, each of which is incorporated herein by reference in its entirety.
  • the ASGPR binding moiety comprises a structure of Formula (V- a): wherein n is an integer from 1 to
  • the compound of Formula (V-a) is selected from:
  • the ASGPR binding moiety comprises a structure of Formula (V- b):
  • A is O or S
  • A’ is O, S, or NH
  • Z is an oligomeric compound, e.g., a linker or TREM, e.g., a linker, a nucleobase, internucleotide linkage, or terminus within the TREM sequence.
  • the ASGPR binding moiety comprises
  • the ASGPR binding moiety is selected from:
  • the ASGPR binding moiety is a compound or substructure disclosed in WO 2017/156012, which is incorporated herein by reference in its entirety.
  • a hydroxyl group within an ASGPR binding moiety is protected, for example, with an acetyl or acetonide moiety. In some embodiments, a hydroxyl group within an ASGPR binding moiety is protected with an acetyl group. In some embodiments, a hydroxyl group within an ASGPR binding moiety is protected with acetonide group. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more hydroxyl groups within an ASGPR binding moiety may be protected, e.g., with an acetyl group or an acetonide group. In some embodiments, all of the hydroxyl groups with in an ASGPR binding moiety are protected.
  • Exemplary TREMs comprising an ASGPR binding moiety may have a binding affinity for an ASGPR of between 0.01 nM to 100 mM.
  • a TREM comprising an ASGPR binding moiety has a binding affinity of less than 10 mM, e.g., 7.5 mM, 5 mM, 2.5 mM, 1 mM, 0.75 mM, 0.5 mM, 0.25 mM, 0.1 mM, 75 nM, 50 nM, 25 nM, 10 nM, 5 nM, or less.
  • Exemplary TREMs comprising an ASGPR binding moiety may be internalized into a cell, e.g., a hepatocyte.
  • a TREM comprising an ASGPR binding moiety has an increased uptake into a cell compared with a TREM that does not comprise an ASGPR binding moiety.
  • a TREM comprising an ASGPR binding moiety may be internalized into a cell more than 1.1, 1.2, 1.3, 1.4, 1.5, 1.75, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100 times or more than a TREM that does not comprise an ASGPR binding moiety.
  • ASGPR moieties are described in further detail in U.S. Patent Nos. 8,828,956; 9,867,882; 10,450,568; 10,808,246; U.S. Patent Publication Nos. 2015/0246133; 2015/0203843; and 2012/0095200; and PCT Publication Nos. WO 2013/166155, 2012/030683, and 2013/166121, each of which are incorporated herein by reference in its entirety.
  • the ASGPR binding moiety comprises at least one linker that connects the carbohydrate to the TREM.
  • the TREM is connected to one or more carbohydrates (e.g., GalNAc moieties, e.g., of Formula (I)), through a linker as described herein.
  • the linker may be monovalent or multivalent, e.g., bivalent, trivalent, tetraval ent, or pentavalent.
  • the linker comprises a structure selected from:
  • q2A, q2B, q3 A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;
  • P 2A , P 2B , P 3A , P 3B , P 4A , P 4B , P 5A P 5B , P 5C , T 2A , T 2B , T 3A , T 3B , T 4A , T 4B , T 4A , T 5B , T 5C are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH 2 , CH 2 NH or CH 2 O;
  • Q 2A , Q 2B , Q 3A , Q 3B , Q 4A , Q 4B , Q 4A , Q 5B , Q 5C are independently for each occurrence absent, alkylene, substitute
  • L 2A , L 2B , L 3A , L 3B , L 4A , L 4B , L 5A , L 5B and L 5C represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; andR a is H or amino acid side chain.
  • a monosaccharide such as GalNAc
  • the linker comprises: wherein L 5A , L 5B and L 5C represent a monosaccharide, such as GalNAc derivative, e.g., as described herein.
  • a cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together.
  • the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).
  • a first reference condition which can, e.g., be selected to mimic or represent intracellular conditions
  • a second reference condition which can, e.g., be selected to mimic or represent conditions found in the blood or serum.
  • Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.
  • redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g.,
  • a cleavable linkage group such as a disulfide bond can be susceptible to pH.
  • the pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3.
  • Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0.
  • Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.
  • a linker can include a cleavable linking group that is cleavable by a particular enzyme.
  • the type of cleavable linking group incorporated into a linker can depend on the cell to be targeted.
  • a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group.
  • Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich.
  • Other cell- types rich in esterases include cells of the lung, renal cortex, and testis.
  • Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.
  • the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue.
  • a degradative agent or condition
  • the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue.
  • the evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals.
  • useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).
  • a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation.
  • An example of reductively cleavable linking group is a disulphide linking group (-S-S-).
  • a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular TREM moiety and particular targeting agent one can look to methods described herein.
  • a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell.
  • the candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions.
  • candidate compounds are cleaved by at most about 10% in the blood.
  • useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions).
  • the rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.
  • a cleavable linker comprises a phosphate-based cleavable linking group.
  • a phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group.
  • An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells.
  • phosphate-based linking groups are -O- P(O)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, -S- P(O)(ORk)-S-, -O-P(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S- P(O)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(O)(Rk)-S-, -O-P(
  • Preferred embodiments are -O- P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S- P(O)(OH)-S-, -O-P(S)(OH)-S-, -S-P(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(O)(H)-O-, -S-P(O)(H)-S-, -O-P(S)(H)-S-, -O-P(S)(H)-S-.
  • a preferred embodiment is -O-P(O)(OH)-O-.
  • a cleavable linker comprises an acid cleavable linking group.
  • An acid cleavable linking group is a linking group that is cleaved under acidic conditions.
  • acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid.
  • specific low pH organelles such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups.
  • Acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids.
  • a preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl.
  • a cleavable linker comprises an ester-based cleavable linking group.
  • An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells.
  • Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups.
  • Ester cleavable linking groups have the general formula -C(O)O-, or -OC(O)-. These candidates can be evaluated using methods analogous to those described above.
  • a cleavable linker comprises a peptide-based cleavable linking group.
  • a peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells.
  • Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides.
  • Peptide-based cleavable groups do not include the amide group (-C(O)NH-).
  • the amide group can be formed between any alkylene, alkenylene or alkynelene.
  • a peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins.
  • the peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group.
  • Peptide-based cleavable linking groups have the general formula - NHCHRAC(O)NHCHRBC(O)- (SEQ ID NO: 13), where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.
  • the ASGPR binding moiety may be bound to any nucleotide position within a domain (ASt Domainl, DH Domain, ACH Domain, VL Domain, TH Domain, and/or ASt Domain2) of a TREM.
  • the ASGPR moiety is bound to a nucleobase, terminus, or internucleotide linkage within a TREM.
  • the ASGPR moiety is bound to a nucleobase within a TREM.
  • the ASGPR binding moiety is bound to any adenine nucleobase within a domain (ASt Domainl, DH Domain, ACH Domain, VL Domain, TH Domain, and/or ASt Domain2) of the TREM.
  • ASGPR binding moiety is bound to any cytosine nucleobase within a domain (ASt Domainl, DH Domain, ACH Domain, VL Domain, TH Domain, and/or ASt Domain2) of the TREM. In an embodiment, it is bound to any guanosine nucleobase within a domain (ASt Domainl, DH Domain, ACH Domain, VL Domain, TH Domain, and/or ASt Domain2) of the TREM. In an embodiment, it is bound to any uracil nucleobase within a domain (ASt Domainl, DH Domain, ACH Domain, VL Domain, TH Domain, and/or ASt Domain2) of the TREM. In an embodiment, it is bound to any thymine nucleobase within a domain (ASt Domainl, DH Domain, ACH Domain, VL Domain, TH Domain, and/or ASt Domain2) of the TREM.
  • the ASGPR binding moiety is present within a TREM at TREM position 1 (e.g., present within a nucleobase at TREM position 1). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 2 (e.g., present within a nucleobase at TREM position 2). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 3 (e.g., present within a nucleobase at TREM position 3). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 4 (e.g., present within a nucleobase at TREM position 4).
  • the ASGPR binding moiety is present within a TREM at TREM position 5 (e.g., present within a nucleobase at TREM position 5). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 6 (e.g., present within a nucleobase at TREM position 6). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 7 (e.g., present within a nucleobase at TREM position 7). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 8 (e.g., present within a nucleobase at TREM position 8). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 9 (e.g., present within a nucleobase at TREM position 9).
  • the ASGPR binding moiety is present within a TREM at TREM position 10 (e.g., present within a nucleobase at TREM position 10). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 11 (e.g., present within a nucleobase at TREM position 11). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 12 (e.g., present within a nucleobase at TREM position 12). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 13 (e.g., present within a nucleobase at TREM position 13).
  • the ASGPR binding moiety is present within a TREM at TREM position 14 (e.g., present within a nucleobase at TREM position 14). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 15 (e.g., present within a nucleobase at TREM position 15). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 16 (e.g., present within a nucleobase at TREM position 16). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 17 (e.g., present within a nucleobase at TREM position 17).
  • the ASGPR binding moiety is present within a TREM at TREM position 18 (e.g., present within a nucleobase at TREM position 18). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 19 (e.g., present within a nucleobase at TREM position 19). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 20 (e.g., present within a nucleobase at TREM position 20). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 21 (e.g., present within a nucleobase at TREM position 21).
  • the ASGPR binding moiety is present within a TREM at TREM position 22 (e.g., present within a nucleobase at TREM position 22). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 23 (e.g., present within a nucleobase at TREM position 23). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 24 (e.g., present within a nucleobase at TREM position 24). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 25 (e.g., present within a nucleobase at TREM position 25). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 26 (e.g., present within a nucleobase at TREM position 26).
  • the ASGPR binding moiety is present within a TREM at TREM position 27 (e.g., present within a nucleobase at TREM position 27). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 28 (e.g., present within a nucleobase at TREM position 28). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 29 (e.g., present within a nucleobase at TREM position 29). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 30 (e.g., present within a nucleobase at TREM position 30).
  • the ASGPR binding moiety is present within a TREM at TREM position 31 (e.g., present within a nucleobase at TREM position 31). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 32 (e.g., present within a nucleobase at TREM position 32). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 33 (e.g., present within a nucleobase at TREM position 33). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 34 (e.g., present within a nucleobase at TREM position 34).
  • the ASGPR binding moiety is present within a TREM at TREM position 35 (e.g., present within a nucleobase at TREM position 35). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 36 (e.g., present within a nucleobase at TREM position 36). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 37 (e.g., present within a nucleobase at TREM position 37). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 38 (e.g., present within a nucleobase at TREM position 38).
  • the ASGPR binding moiety is present within a TREM at TREM position 39 (e.g., present within a nucleobase at TREM position 39). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 40 (e.g., present within a nucleobase at TREM position 40). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 41 (e.g., present within a nucleobase at TREM position 41). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 42 (e.g., present within a nucleobase at TREM position 42). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 43 (e.g., present within a nucleobase at TREM position 43).
  • the ASGPR binding moiety is present within a TREM at TREM position 44 (e.g., present within a nucleobase at TREM position 44). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 45 (e.g., present within a nucleobase at TREM position 45). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 46 (e.g., present within a nucleobase at TREM position 46). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 47 (e.g., present within a nucleobase at TREM position 47).
  • the ASGPR binding moiety is present within a TREM at TREM position 48 (e.g., present within a nucleobase at TREM position 48). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 49 (e.g., present within a nucleobase at TREM position 49).
  • the ASGPR binding moiety is present within a TREM at TREM position 50 (e.g., present within a nucleobase at TREM position 50). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 51 (e.g., present within a nucleobase at TREM position 51). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 52 (e.g., present within a nucleobase at TREM position 52). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 53 (e.g., present within a nucleobase at TREM position 53).
  • the ASGPR binding moiety is present within a TREM at TREM position 54 (e.g., present within a nucleobase at TREM position 54). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 55 (e.g., present within a nucleobase at TREM position 55). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 56 (e.g., present within a nucleobase at TREM position 56). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 57 (e.g., present within a nucleobase at TREM position 57).
  • the ASGPR binding moiety is present within a TREM at TREM position 58 (e.g., present within a nucleobase at TREM position 58). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 59 (e.g., present within a nucleobase at TREM position 59). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 60 (e.g., present within a nucleobase at TREM position 60). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 61 (e.g., present within a nucleobase at TREM position 61).
  • the ASGPR binding moiety is present within a TREM at TREM position 62 (e.g., present within a nucleobase at TREM position 62). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 63 (e.g., present within a nucleobase at TREM position 63). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 64 (e.g., present within a nucleobase at TREM position 64).
  • the ASGPR binding moiety is present within a TREM at TREM position 65 (e.g., present within a nucleobase at TREM position 65). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 66 (e.g., present within a nucleobase at TREM position 66). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 67 (e.g., present within a nucleobase at TREM position 67). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 68 (e.g., present within a nucleobase at TREM position 68).
  • the ASGPR binding moiety is present within a TREM at TREM position 69 (e.g., present within a nucleobase at TREM position 69). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 70 (e.g., present within a nucleobase at TREM position 70). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 71 (e.g., present within a nucleobase at TREM position 71). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 72 (e.g., present within a nucleobase at TREM position 72).
  • the ASGPR binding moiety is present within a TREM at TREM position 73 (e.g., present within a nucleobase at TREM position 73). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 74 (e.g., present within a nucleobase at TREM position 74). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 75 (e.g., present within a nucleobase at TREM position 75). In an embodiment, the ASGPR binding moiety is present within a TREM at TREM position 76 (e.g., present within a nucleobase at TREM position 76).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 1 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 2 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 3 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 4 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 5 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 6 (C).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 7 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 8 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 9 (G).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 10 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 11 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 12 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 13 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 14 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 15 (A).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 16 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 17 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 18 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 19 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 20 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 21 (A).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 22 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 23 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 24 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 25 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 26 (A).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 27 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 28 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 29 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 30 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 31 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 32 (C).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 33 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 34 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 35 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 36 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 37 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 38 (A).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 39 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 40 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 41 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 42 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 43 (A).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 44 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 45 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 46 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 47 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 48 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 49 (C)
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 50 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 51 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 52 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 53 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 54 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 55 (U).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 56 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 57 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 58 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 59 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 60 (U). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 61 (C).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 62 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 63 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 64 (G).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 76 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 75 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 74 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 73 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 72 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 71 (U).
  • the ASGPR binding moiety is bound to a nucleobase at TREM position 70 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 69 (A). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 68 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 67 (G). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 66 (C). In an embodiment, the ASGPR binding moiety is bound to a nucleobase at TREM position 65 (G).
  • the TREM comprising an ASGPR binding moiety comprises a ribonucleic acid (RNA) sequence encoded by a deoxyribonucleic acid (DNA) sequence disclosed in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises an RNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises an RNA sequence encoded by a DNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence encoded by a DNA sequence disclosed in Table 1, e.g., at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence encoded by any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5, 10, 15, 20, 25, or 30 consecutive nucleotides of an RNA sequence encoded by a DNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of an RNA sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of an RNA sequence encoded by a DNA sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence encoded by a DNA sequence disclosed in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an RNA sequence encoded by a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence encoded by a DNA sequence with at least 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, 99% or 100% identity to a DNA sequence provided in Table 1, e.g., any one of SEQ ID NOs: 1-451 disclosed in Table 1.
  • the TREM comprising an ASGPR binding moiety comprises a ribonucleic acid (RNA) sequence encoded by a deoxyribonucleic acid (DNA) sequence disclosed in Table 4, e.g., any one of SEQ ID NOs: 452-561 disclosed in Table 4.
  • the TREM comprising an ASGPR binding moiety comprises an RNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence encoded by a DNA sequence provided in Table 4, e.g., any one of SEQ ID NOs: 452-561 disclosed in Table 4.
  • the TREM comprising an ASGPR binding moiety comprises an RNA sequence encoded by a DNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a DNA sequence provided in Table 4, e.g., any one of SEQ ID NOs: 452-561 disclosed in Table 4.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence encoded by a DNA sequence provided in Table 4, e.g., any one of SEQ ID NOs: 452-561 disclosed in Table 4.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an RNA sequence encoded by a DNA sequence provided in Table 4, e.g., any one of SEQ ID NOs: 452-561 disclosed in Table 4.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of an RNA sequence encoded by a DNA sequence with at least 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, 99% or 100% identity to a DNA sequence provided in Table 4, e.g., any one of SEQ ID NOs: 452-561 disclosed in Table 4.
  • the TREM comprising an ASGPR binding moiety is a compound provided in Table 12, e.g., any one of Compound Nos. 99-131. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 99. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 100. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 101. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 102. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 103. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 104.
  • the TREM comprising an ASGPR binding moiety is Compound 105. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 106. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 107. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 108. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 109. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 110. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 111. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 112.
  • the TREM comprising an ASGPR binding moiety is Compound 113. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 114. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 115. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 116. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 117. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 118. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 119. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 120.
  • the TREM comprising an ASGPR binding moiety is Compound 121. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 122. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 123. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 124. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 125. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 126. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 127. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 128.
  • the TREM comprising an ASGPR binding moiety is Compound 129. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 130. In an embodiment, the TREM comprising an ASGPR binding moiety is Compound 131.
  • the TREM comprising an ASGPR binding moiety comprises a compound having an RNA sequence at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to an RNA sequence of a TREM provided in Table 12, e.g., any one of Compounds 100-131 provided in Table 12.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of a TREM provided in Table 12, e.g., any one of Compounds 100-131 disclosed in Table 12.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of a TREM which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to TREM provided in Table 12, e.g., any one of Compounds 100-131 disclosed in Table 12.
  • the TREM comprising an ASGPR binding moiety comprises a sequence provided in Table 12, e.g., any one of SEQ ID NOs: 622-654.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 622.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 623.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 624.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 625.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 626.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 628. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 629. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 630. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 631. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 632. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 633. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 634.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 635. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 636. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 637. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 638. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 639. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 640. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 641.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 642. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 643. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 644. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 645. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 646. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 647. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 648.
  • the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 649. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 650. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 651. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 652. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 653. In an embodiment, the TREM comprising an ASGPR binding moiety comprises SEQ ID NO. 654.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that is at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to a sequence of a TREM provided in Table 12, e.g., any one of SEQ ID NOs. 622-654 provided in Table 12.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of a TREM provided in Table 12, e.g, any one of SEQ ID NOs. 622-654 disclosed in Table 12.
  • the TREM comprising an ASGPR binding moiety comprises at least 5 ribonucleotides (nt), 10 nt, 15 nt, 20 nt, 25 nt, 30 nt, 35 nt, 40 nt, 45 nt, 50 nt, 55 nt or 60 nt (but less than the full length) of a TREM which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to TREM provided in Table 12, e.g., any one of SEQ ID NOs. 622-654 disclosed in Table 12.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs no more than 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18, nt, or 20 nt from a TREM provided in Table 12, e.g. ,any one of SEQ ID NOs. 622-652 provided in Table 12.
  • the TREM comprising an ASGPR binding moiety is at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO. 622. In an embodiment, the TREM comprising an ASGPR binding moiety is at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO. 650.
  • the TREM comprising an ASGPR binding moiety is at least 60%, 65%, 70%, 75%, 80%, 82%, 85%, 87%, 88%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO. 653.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs comprises by least 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18 nt, 20 nt, 25 nt, 30 nt, 40 nt, 45 nt, 50 nt, 55 nt, or more from SEQ ID NO. 622.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs no more than 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18, nt, or 20 nt from SEQ ID NO. 622.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs comprises by least 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18 nt, 20 nt, 25 nt, 30 nt, 40 nt, 45 nt, 50 nt, 55 nt, or more from SEQ ID NO. 650.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs no more than 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18, nt, or 20 nt from SEQ ID NO. 650.
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs comprises by least 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18 nt, 20 nt, 25 nt, 30 nt, 40 nt, 45 nt, 50 nt, 55 nt, or more from SEQ ID NO. 653.
  • nt ribonucleotide
  • the TREM comprising an ASGPR binding moiety comprises a sequence that differs no more than 1 ribonucleotide (nt), 2 nt, 3 nt, 4 nt, 5 nt, 6 nt, 7 nt, 8 nt, 9 nt, 10 nt, 12 nt, 14 nt, 16 nt, 18, nt, or 20 nt from SEQ ID NO. 653.
  • nt ribonucleotide
  • a TREM entity (e.g, a TREM, a TREM core fragment or a TREM fragment described herein) further comprises a chemical modification, e.g., a modification described in any one of Tables 5-9, in addition to an ASGPR binding moiety.
  • a chemical modification can be made according to methods known in the art.
  • a chemical modification is a modification that a cell, e.g., a human cell, does not make on an endogenous tRNA.
  • a chemical modification is a modification that a cell, e.g., a human cell, can make on an endogenous tRNA, but wherein such modification is in a location in which it does not occur on a native tRNA.
  • the chemical modification is in a domain, linker or arm which does not have such modification in nature.
  • the chemical modification is at a position within a domain, linker or arm, which does not have such modification in nature.
  • the chemical modification is on a nucleotide which does not have such modification in nature.
  • the chemical modification is on a nucleotide at a position within a domain, linker or arm, which does not have such modification in nature.
  • nucleic acids featured in the disclosure can be synthesized and/or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry,” Beaucage, S.L. et al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is hereby incorporated herein by reference.
  • Modifications include, for example, end modifications, e.g., 5 ’-end modifications (phosphorylation, conjugation, inverted linkages) or 3 ‘-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g. , at the 2’-position or 4’-position) or replacement of the sugar; and/or backbone modifications, including modification or replacement of the phosphodiester linkages.
  • end modifications e.g., 5 ’-end modifications (phosphorylation, conjugation, inverted linkages) or 3 ‘-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.
  • base modifications e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abas
  • TREM compounds useful in the embodiments described herein include, but are not limited to TREMs containing modified backbones or no natural intemucleoside linkages.
  • TREMs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone.
  • modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.
  • a modified TREMs will have a phosphorus atom in its intemucleoside backbone.
  • Modified TREM backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3 ’-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3 ’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’.
  • Various salts, mixed salts and free acid forms are also included.
  • Modified TREM backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl intemucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl intemucleoside linkages, or one or more short chain heteroatomic or heterocyclic intemucleoside linkages.
  • patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312;
  • RNA mimetics are contemplated for use in TREMs, in which both the sugar and the intemucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
  • the base units are maintained for hybridization with an appropriate nucleic acid target compound.
  • an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA).
  • PNA peptide nucleic acid
  • the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone.
  • the nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
  • Some embodiments featured in the disclosure include TREMs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular — CH 2 — NH — CH 2 -, -CH 2 -N(CH 3 )-0-CH 2 - [known as a methylene (methylimino) or MMI backbone], - CH 2 -O- N(CH 3 )-CH 2 -, -CH 2 -N(CH 3 )-N(CH 3 )-CH 2 - and -N(CH 3 )-CH 2 -CH 2 - [wherein the native phosphodiester backbone is represented as — O — P — O — CH 2 — ] of the above-referenced U.S.
  • Patent No. 5,489,677 and the amide backbones of the above- referenced U.S. Patent No. 5,602,240.
  • the TREMs featured herein have morpholino backbone structures of the above-referenced U.S. Patent No. 5,034,506.
  • the TREMs featured herein can include one of the following at the 2’-position: OH; F; 0- , S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to C 10 alkyl or C2 to C 10 alkenyl and alkynyl.
  • Exemplary suitable modifications include O[(CH 2 ) n O] m CH 3 , O(CH 2 ).
  • n OCH 3 O(CH 2 ) n NH 2 , O(CH 2 ) n CH 3 , O(CH 2 ) n ONH 2 , and 0(CH 2 )nON[(CH 2 )nCH 3 )] 2 , where n and m are from 1 to about 10.
  • TREMs may include one of the following at the 2’ position: Ci to C 10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O- alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ON0 2 , N0 2 , N3, NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of a TREM, or a group for improving the pharmacodynamic properties of a TREM, and other substituents having similar properties.
  • the modification includes a 2’ -methoxy ethoxy (2’-0 — CH 2 CH 2 OCH 3 , also known as 2’ -O-(2 -methoxy ethyl) or 2’-M0E) (Martin et al., Helv. Chim. Acta, 1995, 78:486- 504) i.e., an alkoxy-alkoxy group.
  • 2’- dimethylaminooxyethoxy i.e., a O(CH 2 ) 2 ON(CH3) 2 group, also known as 2’-DMAOE, as described in examples herein below
  • 2’ -dimethylaminoethoxy ethoxy also known in the art as 2’-O-dimethylaminoethoxyethyl or 2’-DMAEOE
  • 2’-O-CH 2 -O-CH 2 -N(CH 2 ) 2 i.e., 2’-O-CH 2 -O-CH 2 -N(CH 2 ) 2 .
  • TREMs can also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
  • base nucleobase
  • unmodified or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
  • Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5 -hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2- propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2- thiothymine and 2- thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6- azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8- thiol, 8-thioalkyl, 8- hydroxyl anal other 8-substituted adenines and guanines, 5-halo,
  • nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley- VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858- 859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993.
  • nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention.
  • These include 5- substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
  • 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6- 1.2°C (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2’-0-methoxyethyl sugar modifications.
  • the TREM can also be modified to include one or more bicyclic sugar moi eties.
  • a "bicyclic sugar” is a furanosyl ring modified by the bridging of two atoms.
  • A"bicyclic nucleoside" (“BNA”) is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system.
  • the bridge connects the 4’ -carbon and the 2’ -carbon of the sugar ring.
  • an agent of the invention may include the RNA of a TREM can also be modified to include one or more locked nucleic acids (LNA).
  • LNA locked nucleic acids
  • a locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2’ and 4’ carbons.
  • an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4’-CH2-O-2’ bridge. This structure effectively "locks" the ribose in the 3’-endo structural conformation.
  • the addition of locked nucleic acids to oligonucleotide sequences has been shown to increase their stability in serum, and to reduce off-target effects (Elmen, J. et al, (2005) Nucleic Acids Research 33(l):439-447; Mook, OR. et al, (2007) Mol Cane Ther 6(3):833- 843; Grunweller, A. et al, (2003) Nucleic Acids Research 31(12):3185-3193)
  • a TREM, a TREM core fragment or a TREM fragment described herein comprises a chemical modification provided in Table 5, or a combination thereof.
  • Table 5 Exemplary modifications
  • a TREM, a TREM core fragment or a TREM fragment described herein comprises a modification provided in Table 6, or a combination thereof.
  • the modifications provided in Table 6 occur naturally in RNAs, and are used herein on a synthetic TREM, a TREM core fragment or a TREM fragment at a position that does not occur in nature.
  • Table 6 Additional exemplary modifications
  • a TREM, a TREM core fragment or a TREM fragment described herein comprises a chemical modification provided in Table 7, or a combination thereof.
  • Table 7 Additional exemplary chemical modifications
  • a TREM, a TREM core fragment or a TREM fragment described herein comprises a chemical modification provided in Table 8, or a combination thereof.
  • a TREM, a TREM core fragment or a TREM fragment described herein comprises a non-naturally occurring modification provided in Table 9, or a combination thereof.
  • Table 9 Exemplary non-naturally occurring backbone modifications TREM, TREM core fragment and TREM fragment fusions
  • a TREM, a TREM core fragment or a TREM fragment disclosed herein comprises an additional moiety, e.g., a fusion moiety.
  • the fusion moiety can be used for purification, to alter folding of the TREM, TREM core fragment or TREM fragment, or as a targeting moiety.
  • the fusion moiety can comprise a tag, a linker, can be cleavable or can include a binding site for an enzyme.
  • the fusion moiety can be disposed at the N terminal of the TREM or at the C terminal of the TREM, TREM core fragment or TREM fragment.
  • the fusion moiety can be encoded by the same or different nucleic acid molecule that encodes the TREM, TREM core fragment or TREM fragment.
  • a TREM disclosed herein comprises a consensus sequence provided herein.
  • a TREM disclosed herein comprises a consensus sequence of Formula I ZZZ , wherein zzz indicates any of the twenty amino acids and Formula I corresponds to all species.
  • a TREM disclosed herein comprises a consensus sequence of Formula
  • a TREM disclosed herein comprises a consensus sequence of Formula
  • zzz indicates any of the twenty amino acids: alanine, arginine, asparagine, aspartate, cysteine, glutamine, glutamate, glycine, histidine, isoleucine, methionine, leucine, lysine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
  • a TREM disclosed herein comprises a property selected from the following: a) under physiological conditions residue R 0 forms a linker region, e.g., a Linker 1 region; b) under physiological conditions residues R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 and residues R 65 -R 66 - R 67 -R 68 -R 69 -R 70 -R 71 form a stem region, e.g., an AStD stem region; c) under physiological conditions residues R 8 -R 9 forms a linker region, e.g., a Linker 2 region; d) under physiological conditions residues -R 10 -R 11 -R 12 -R 13 -R 14 R 15 -R 16 -R 17 -R 18 -R 19 -R 20 - R 21 -R 22 -R 23 -R 24 -R 25 -R 26 -R 27 -R 28 form
  • a TREM disclosed herein comprises the sequence of Formula IALA (SEQ ID NO: 562),
  • R 14 , R 57 are independently A or absent;
  • R 26 A, C, G or absent;
  • R 5 , R 6 , R 15 , R 16 , R 21 , R 30 , R 31 , R 32 , R 34 , R 37 , R 41 , R 42 , R 43 , R 44 , R 45 , R 48 , R 49 , R 50 , R 58 , R 59 , R 63 , R 64 , R 66 , R 67 are independently N or absent;
  • R 1 , R 9 , R 20 , R 38 , R 40 , R 51 , R 52 , R 56 are independently A, G or absent;
  • R 7 , R 22 , R 25 , R 27 , R 29 , R 46 , R 53 , R 72 are independently A, G, U or absent;
  • R 24 , R 69 are independently A, U or absent;
  • R 70 , R 71 are independently C or absent;
  • R 12 , R 33 , R 36 , R 62 , R 68 are independently C, G, U or absent;
  • R 13 , R 17 , R 28 , R 39 , R 55 , R 60 , R 61 are independently C, U or absent;
  • R 10 , R 19 , R 23 are independently G or absent;
  • R 2 G, U or absent
  • R 8 , Ris, R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula IIALA (SEQ ID NO: 563),
  • R 0 , R 18 are absent
  • R 14 , R 24 , R 57 are independently A or absent;
  • R 15 , R 26 , R 64 are independently A, C, G or absent;
  • R 16 , R 31 , R 50 , R 59 are independently N or absent;
  • R 11 , R 32 , R 37 , R 41 , R 43 , R 45 , R 49 , R 65 , R 66 are independently A, C, U or absent;
  • R 1 , R 5 , R 9 , R 25 , R 27 , R 38 , R 40 , R 46 , R 51 , R 56 are independently A, G or absent;
  • R 7 , R 22 , R 29 , R 42 , R 44 , R 53 , Res, R 72 are independently A, G, U or absent;
  • R 6 , R 35 , R 69 are independently A, U or absent;
  • R 55 , R 60 , R 70 , R 71 are independently C or absent;
  • R 3 C, G or absent;
  • R 12 , R 36 , R 48 are independently C, G, U or absent;
  • R 13 , R 17 , R 28 , R 30 , R 34 , R 39 , R 58 , R 61 , R 62 , R 67 , R 68 are independently C, U or absent;
  • R 4 , R 10 , R 19 , R 20 , R 23 , R 52 are independently G or absent;
  • R 21 , R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula IIIALA (SEQ ID NO: 564),
  • R 0 , R 18 are absent
  • R 14 , R 24 , R 57 , R 72 are independently A or absent;
  • R 15 , R 26 , R 64 are independently A, C, G or absent;
  • R 16 , R 31 , R 50 are independently N or absent;
  • R 11 , R 32 , R 37 , R 41 , R 43 , R 45 , R 49 , R 65 , R 66 are independently A, C, U or absent;
  • R 7 , R 22 , R 29 , R 42 , R 44 , R 53 , R 63 are independently A, G, U or absent;
  • R 6 , R 35 are independently A, U or absent;
  • R 13 , R 17 , R 28 , R 30 , R 34 , R 39 , R 58 , R 62 , R 67 , R 68 are independently C, U or absent;
  • R 1 , R 2 , R 3 , R 4 , R 10 , R 19 , R 20 , R 23 , R 52 are independently G or absent;
  • R 33 , R 36 are independently G, U or absent;
  • R 8 , R 21 , R 54 , R 69 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I ARG (SEQ ID NO: 565),
  • R 57 A or absent;
  • R 9 ,R 27 are independently A,C,G or absent;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 ,R 11 ,R 12 ,R 16 , R 21 , R 22 , R 23 ,R 25 ,R 26 ,R 29 ,R 30 ,R 31 ,R 32 ,R 33 ,R 34 ,R 37 , R 42 , R 44 , R 45 , R 46 ,R 48 ,R 49 ,R 50 ,R 51 ,R 58 ,R 62 ,R 63 ,R 64 ,R 65 ,R 66 ,R 67 ,R 68 ,R 69 ,R 70 ,R 71 are independently N or absent;
  • R 13 ,R 17 ,R 41 are independently A,C,U or absent;
  • R 19 ,R 20 ,R 24 ,R 40 ,R 56 are independently A,G or absent;
  • R 14 ,R 15 ,R 72 are independently A,G,U or absent;
  • R 18 A,U or absent
  • R 38 C or absent
  • R 35 ,R 43 ,R 61 are independently C,G,U or absent;
  • R 28 ,R 55 ,R 59 ,R 60 are independently C,U or absent;
  • R 0 ,R 10 ,R 52 are independently G or absent;
  • R 8 ,R 39 are independently G,U or absent;
  • R 36 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II ARG (SEQ ID NO: 566),
  • R 24 ,R 57 are independently A or absent;
  • R 41 A,C or absent
  • R 3 ,R 7 ,R 34 ,R 50 are independently A,C,G or absent;
  • R 2 ,R 5 ,R 6 ,R 12 ,R 26 ,R 32 ,R 37 ,R 44 ,R 58 ,R 66 ,R 67 ,R 68 ,R 70 are independently N or absent;
  • R 49 ,R 71 are independently A,C,U or absent;
  • R 1 ,R 15 ,R 19 ,R 25 ,R 27 ,R 40 ,R 45 ,R 46 ,R 56 ,R 72 are independently A,G or absent;
  • R 14 ,R 29 ,R 63 are independently A,G,U or absent;
  • R 16 ,R 21 are independently A,U or absent;
  • R 38 ,R 61 are independently C or absent;
  • R 33 ,R 48 are independently C,G or absent;
  • R 4 ,R 9 ,R 11 ,R 43 ,R 62 ,R 64 ,R 69 are independently C,G,U or absent;
  • R 13 ,R 22 ,R 28 ,R 30 ,R 31 ,R 35 ,R 55 ,R 60 ,R 65 are independently C,U or absent;
  • R 0 ,R 10 ,R 20 ,R 23 ,R 51 ,R 52 are independently G or absent;
  • R 8 ,R 39 ,R 42 are independently G,U or absent;
  • R 17 ,R 36 ,R 53 ,R 54 ,R 59 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III ARG (SEQ ID NO: 567),
  • R 18 is absent;
  • R 15 ,R 21 ,R 24 ,R 41 ,R 57 are independently A or absent;
  • R 34 ,R 44 are independently A,C or absent;
  • R 3 ,R 5 ,R 58 are independently A,C,G or absent;
  • R 2 ,R 6 ,R 66 ,R 70 are independently N or absent;
  • R 37 ,R 49 are independently A,C,U or absent;
  • R 1 ,R 25 ,R 29 ,R 40 ,R 45 ,R 46 ,R 50 are independently A,G or absent;
  • R 14 ,R 63 ,R 68 are independently A,G,U or absent;
  • R 16 A,U or absent
  • R 38 ,R 61 are independently C or absent;
  • R 7 ,R 11 ,R 12 ,R 26 ,R 48 are independently C,G or absent;
  • R 64 ,R 67 ,R 69 are independently C,G,U or absent;
  • R 4 ,R 13 ,R 22 ,R 28 ,R 30 ,R 31 ,R 35 ,R 43 ,R 55 ,R 60 ,R 62 ,R 65 ,R 71 are independently C,U or absent;
  • R 0 ,R 10 ,R 19 ,R 20 ,R 23 ,R 27 ,R 33 ,R 51 ,R 52 ,R 56 ,R 72 are independently G or absent;
  • a TREM disclosed herein comprises the sequence of Formula I ASN (SEQ ID NO: 568),
  • R 41 A or absent
  • R 14 ,R 48 ,R 56 are independently A,C,G or absent;
  • R 2 , R 4 , R 5 ,R 6 ,R 12 ,R 17 ,R 26 ,R 29 ,R 30 ,R 31 ,R 44 ,R 45 , R 46 , R 49 , R 50 ,R 58 ,R 62 ,R 63 ,R 65 ,R 66 ,R 67 ,R 68 ,R 70 ,R 71 are independently N or absent;
  • R 11 ,R 13 ,R 22 ,R 42 ,R 55 ,R 59 are independently A,C,U or absent;
  • R 9 ,R 15 ,R 24 ,R 27 ,R 34 ,R 37 ,R 51 ,R 72 are independently A,G or absent;
  • R 1 ,R 7 ,R 25 ,R 69 are independently A,G,U or absent;
  • R 40 ,R 57 are independently A,U or absent;
  • R 60 C or absent;
  • R 33 C,G or absent;
  • R 21 ,R 32 ,R 43 ,R 64 are independently C,G,U or absent;
  • R 3 ,R 16 ,R 28 ,R 35 ,R 36 ,R 61 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 ,R 52 are independently G or absent;
  • R 54 G,U or absent
  • a TREM disclosed herein comprises the sequence of Formula II ASN (SEQ ID NO: 569),
  • R 0 ,R 18 are absent
  • R 24 ,R 41 ,R 46 ,R 62 are independently A or absent
  • R 59 A,C or absent
  • R 14 ,R 56 ,R 66 are independently A,C,G or absent;
  • R 17 ,R 29 are independently N or absent;
  • R 11 ,R 26 ,R 42 ,R 55 are independently A,C,U or absent;
  • R 1 ,R 9 ,R 12 ,R 15 ,R 25 ,R 34 ,R 37 ,R 48 ,R 51 ,R 67 ,R 68 ,R 69 ,R 70 ,R 72 are independently A,G or absent;
  • R 44 ,R 45 ,R 58 are independently A,G,U or absent;
  • R 40 ,R 57 are independently A,U or absent;
  • R 5 ,R 28 ,R 60 are independently C or absent;
  • R 33 ,R 65 are independently C,G or absent;
  • R 21 ,R 43 ,R 71 are independently C,G,U or absent;
  • R 3 ,R 6 ,R 13 ,R 22 ,R 32 ,R 35 ,R 36 ,R 61 ,R 63 ,R 64 are independently C,U or absent;
  • R 7 ,R 10 ,R 19 ,R 20 ,R 27 ,R 49 ,R 52 are independently G or absent;
  • R 54 G,U or absent
  • R 2 ,R 4 ,R 8 ,R 16 ,R 23 ,R 30 ,R 31 ,R 38 ,R 39 ,R 50 ,R 53 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III ASN (SEQ ID NO: 570), R 0 - R 1 - R 2 - R 3 -R 4 -R 5 -R 6 -R 7 -R 8 -R 9 -R 10 -R 11 -R 12 -R 13 -R 14 -R 15 -R 16 -R 17 -R 18 -R 19 -R 20 -R 21 -R 22 - R 23 -R 24 -R 25 -R 26 -R 27 -R 28 -R 29 -R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -R 39 -R 40 -R 41 -R 42 - R 43 - R 44 -R 45 - R 46 - [R 47 ] x -R 48 -R 49 -R 50 -R 51 -R 52 -R 53 -R 54 -R
  • R 24 ,R 40 ,R 41 ,R 46 ,R 62 are independently A or absent;
  • R 59 A,C or absent
  • R 14 ,R 56 ,R 66 are independently A,C,G or absent;
  • R 11 ,R 26 ,R 42 ,R 55 are independently A,C,U or absent;
  • R 1 ,R 9 ,R 12 ,R 15 ,R 34 ,R 37 ,R 48 ,R 51 ,R 67 ,R 68 ,R 69 ,R 70 are independently A,G or absent;
  • R 44 ,R 45 ,R 58 are independently A,G,U or absent;
  • R 57 A,U or absent
  • R 5 ,R 28 ,R 60 are independently C or absent;
  • R 33 ,R 65 are independently C,G or absent;
  • R 17 ,R 21 ,R 29 are independently C,G,U or absent;
  • R 3 ,R 6 ,R 13 ,R 22 ,R 32 ,R 35 ,R 36 ,R 43 ,R 61 ,R 63 ,R 64 ,R 71 are independently C,U or absent;
  • R 7 ,R 10 ,R 19 ,R 20 ,R 25 ,R 27 ,R 49 ,R 52 ,R 72 are independently G or absent;
  • R 54 G,U or absent
  • R 2 ,R 4 ,R 8 ,R 16 ,R 23 ,R 30 ,R 31 ,R 38 ,R 39 ,R 50 ,R 53 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I ASP (SEQ ID NO: 571),
  • R 24 ,R 71 are independently A,C or absent;
  • R 33 ,R 46 are independently A,C,G or absent;
  • R 2 ,R 3 ,R 4 ,R 5 ,R 6 ,R 12 ,R 16 ,R 22 ,R 26 ,R 29 ,R 31 ,R 32 ,R 44 ,R 48 ,R 49 ,R 58 ,R 63 ,R 64 ,R 66 ,R 67 ,R 68 ,R 69 are independently N or absent;
  • R 13 ,R 21 ,R 34 ,R 41 ,R 57 ,R 65 are independently A,C,U or absent;
  • R 9 ,R 10 ,R 14 ,R 15 ,R 20 ,R 27 ,R 37 ,R 40 ,R 51 ,R 56 ,R 72 are independently A,G or absent;
  • R 7 ,R 25 ,R 42 are independently A,G,U or absent;
  • R 39 C or absent;
  • R 50 ,R 62 are independently C,G or absent;
  • R 30 ,R 43 ,R 45 ,R 55 ,R 70 are independently C,G,U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II ASP (SEQ ID NO: 572),
  • R 0 ,R 17 ,R 18 R 23 are independently absent;
  • R 9 ,R 40 are independently A or absent;
  • R 24 ,R 71 are independently A,C or absent;
  • R 67 ,R 68 are independently A,C,G or absent;
  • R 2 ,R 6 ,R 66 are independently N or absent;
  • R 57 ,R 63 are independently A,C,U or absent;
  • R 10 ,R 14 ,R 27 ,R 33 ,R 37 ,R 44 ,R 46 ,R 51 ,R 56 ,R 64 ,R 72 are independently A,G or absent;
  • R 7 ,R 12 ,R 26 ,R 65 are independently A,U or absent;
  • R 39 ,R 61 ,R 62 are independently C or absent;
  • R 3 ,R 31 ,R 45 ,R 70 are independently C,G or absent;
  • R 4 ,R 5 ,R 29 ,R 43 ,R 55 are independently C,G,U or absent;
  • R 8 ,R 11 ,R 13 ,R 30 ,R 32 ,R 34 ,R 35 ,R 41 ,R 48 ,R 53 ,R 59 ,R 60 are independently C,U or absent;
  • R 15 ,R 19 ,R 20 ,R 25 ,R 42 ,R 50 ,R 52 are independently G or absent;
  • R 1 ,R 22 ,R 49 ,R 58 ,R 69 are independently G,U or absent;
  • R 16 ,R 21 ,R 28 ,R 36 ,R 38 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III ASP (SEQ ID NO: 573),
  • R 0 R 17 ,R 18 R 23 are absent
  • R 9 ,R 12 ,R 40 ,R 65 ,R 71 are independently A or absent
  • R 2 ,R 24 ,R 57 are independently A,C or absent;
  • R 6 ,R 14 ,R 27 ,R 46 ,R 51 ,R 56 ,R 64 ,R 67 ,R 68 are independently A,G or absent;
  • R 3 ,R 31 ,R 35 ,R 39 ,R 61 ,R 62 are independently C or absent;
  • R 66 C,G or absent;
  • R 5 ,R 8 ,R 29 ,R 30 ,R 32 ,R 34 ,R 41 ,R 43 ,R 48 ,R 55 ,R 59 ,R 60 ,R 63 are independently C,U or absent;
  • R 10 ,R 15 ,R 19 ,R 20 ,R 25 ,R 33 ,R 37 ,R 42 ,R 44 ,R 45 ,R 49 ,R 50 ,R 52 ,R 69 ,R 70 ,R 72 are independently G or absent;
  • R 22 ,R 58 are independently G,U or absent;
  • R 1 ,R 4 ,R 7 ,R 11 ,R 13 ,R 16 ,R 21 ,R 26 ,R 28 ,R 36 ,R 38 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I CYS (SEQ ID NO: 574),
  • R 14 ,R 39 ,R 57 are independently A or absent;
  • R 41 A,C or absent
  • R 10 ,R 15 ,R 27 ,R 33 ,R 62 are independently A,C,G or absent;
  • R 2 C, G or absent
  • R 21 ,R 28 ,R 43 ,R 50 are independently C,G,U or absent
  • R 11 ,R 22 ,R 23 ,R 35 ,R 36 ,R 59 ,R 60 ,R 61 ,R 71 ,R 72 are independently C,U or absent;
  • R 1 ,Ri9 are independently G or absent;
  • R 8 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II CYS (SEQ ID NO: 575),
  • R 14 ,R 24 ,R 26 ,R 29 ,R 39 ,R 41 ,R 45 ,R 57 are independently A or absent;
  • R 44 A,C or absent
  • R 27 ,R 62 are independently A,C,G or absent
  • R 16 A,C,G,U or absent
  • R 30 ,R 70 are independently A,C,U or absent;
  • R 5 ,R 7 ,R 9 ,R 25 ,R 34 ,R 37 ,R 40 ,R 46 ,R 52 ,R 56 ,R 58 ,R 66 are independently A,G or absent;
  • R 20 ,R 51 are independently A,G,U or absent;
  • R 35 ,R 38 ,R 43 ,R 55 ,R 69 are independently C or absent;
  • R 2 ,R 4 ,R 15 are independently C,G or absent;
  • R 13 C,G,U or absent
  • R 6 ,R 11 ,R 28 ,R 36 ,R 48 ,R 49 ,R 50 ,R 60 ,R 61 ,R 67 ,R 68 ,R 71 ,R 72 are independently C,U or absent;
  • R 1 ,R 3 ,R 10 ,R 19 ,R 33 ,R 63 are independently G or absent;
  • R 8 ,R 17 ,R 21 ,R 64 are independently G,U or absent;
  • R 12 ,R 22 ,R 31 ,R 32 ,R 42 ,R 53 ,R 54 ,R 65 are independently U or absent;
  • R 59 U, or absent
  • a TREM disclosed herein comprises the sequence of Formula III CYS (SEQ ID NO: 576),
  • R 14 ,R 24 ,R 26 ,R 29 ,R 34 ,R 39 ,R 41 ,R 45 ,R 57 ,R 58 are independently A or absent;
  • R 44 ,R 70 are independently A,C or absent;
  • R 62 A,C,G or absent;
  • R 16 N or absent
  • R 5 ,R 7 ,R 9 ,R 20 ,R 40 ,R 46 ,R 51 ,R 52 ,R 56 ,R 66 are independently A,G or absent;
  • R 28 ,R 35 ,R 38 ,R 43 ,R 55 ,R 67 ,R 69 are independently C or absent;
  • R 4 ,R 15 are independently C,G or absent;
  • R 6 ,R 11 ,R 13 ,R 30 ,R 48 ,R 49 ,R 50 ,R 60 ,R 61 ,R 68 ,R 71 ,R 72 are independently C,U or absent;
  • R 1 ,R 2 ,R 3 , R 10 ,R 19 ,R 25 ,R 27 ,R 33 ,R 37 ,R 63 are independently G or absent;
  • R 8 ,R 21 ,R 64 are independently G,U or absent;
  • R 12 ,R 17 ,R 22 ,R 31 ,R 32 ,R 36 ,R 42 ,R 53 ,R 54 , R 59 ,R 65 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I GLN (SEQ ID NO: 577), R 0 - R 1 - R 2 - R 3 -R 4 -R 5 -R 6 -R 7 -R 8 -R 9 -R 10 -R 11 -R 12 -R 13 -R 14 -R 15 -R 16 -R 17 -R 18 -R 19 -R 20 -R 21 -R 22 - R 23 -R 24 -R 25 -R 26 -R 27 -R 28 -R 29 -R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -R 39 -R 40 -R 41 -R 42 - R 43 - R 44 -R 45 - R 46 - [R 47 ] x -R 48 -R 49 -R 50 -R 51 -R 52 -R 53 -R 54 -
  • R 14 ,R 24 ,R 57 are independently A or absent;
  • R 9 ,R 26 ,R 27 ,R 33 ,R 56 are independently A,C,G or absent;
  • R 1 ,R 7 ,R 72 are independently A,G,U or absent;
  • R 3 ,R 11 ,R 37 ,R 60 ,R 64 are independently C,G,U or absent;
  • R 28 ,R 35 ,R 55 ,R 59 ,R 61 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 are independently G or absent;
  • R 39 G,U or absent
  • R 8 ,R 36 ,R 38 ,R 53 ,R 54 are independently U or absent;
  • R 14 ,R 24 ,R 57 are independently A or absent;
  • R 17 ,R 71 are independently A,C or absent;
  • R 25 ,R 26 ,R 33 ,R 44 ,R 46 ,R 56 ,R 69 are independently A,C,G or absent;
  • R 4 ,R 5 ,R 12 ,R 22 ,R 29 ,R 30 ,R 48 ,R 49 ,R 63 ,R 67 ,R 68 are independently N or absent;
  • R 31 ,R 43 ,R 62 ,R 65 ,R 70 are independently A,C,U or absent;
  • R 15 ,R 27 ,R 34 ,R 40 ,R 41 ,R 51 ,R 52 are independently A,G or absent;
  • R 2 ,R 7 ,R 21 ,R 45 ,R 50 ,R 58 ,R 66 ,R 72 are independently A,G,U or absent;
  • R 3 ,R 13 ,R 32 ,R 37 ,R 42 ,R 60 ,R 64 are independently C,G,U or absent;
  • R 6 ,R 11 ,R 28 ,R 35 ,R 55 ,R 59 ,R 61 are independently C,U or absent;
  • R 9 ,R 10 ,R 19 ,R 20 are independently G or absent;
  • R 1 ,R 16 ,R 39 are independently G,U or absent;
  • R 8 ,R 36 ,R 38 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III GLN (SEQ ID NO: 579),
  • R 5 ,R 25 ,R 26 ,R 46 ,R 56 ,R 69 are independently A,C,G or absent;
  • R 4 ,R 22 ,R 29 ,R 30 ,R 48 ,R 49 ,R 63 ,R 68 are independently N or absent;
  • R 43 ,R 62 ,R 65 ,R 70 are independently A,C,U or absent;
  • R 15 ,R 27 ,R 33 ,R 34 ,R 40 ,R 51 ,R 52 are independently A,G or absent;
  • R 2 ,R 7 ,R 12 ,R 45 ,R 50 ,R 58 ,R 66 are independently A,G,U or absent;
  • R 3 I A,U or absent;
  • R 32 ,R 44 ,R 60 are independently C,G or absent;
  • R 3 ,R 13 ,R 37 ,R 42 ,R 64 ,R 67 are independently C,G,U or absent;
  • R 6 ,R 11 ,R 28 ,R 35 ,R 55 ,R 59 ,R 61 are independently C,U or absent;
  • R 9 ,R 10 ,R 19 ,R 20 are independently G or absent;
  • R 1 ,R 21 ,R 39 ,R 72 are independently G,U or absent;
  • R 8 ,R 16 ,R 36 ,R 38 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I GLU (SEQ ID NO: 580),
  • R 0 absent;
  • R 34 ,R 43 ,R 68 ,R 69 are independently A,C,G or absent;
  • R 1 ,R 2 ,R 5 ,R 6 ,R 9 ,R 12 ,R 16 ,R 20 ,R 21 ,R 26 ,R 27 ,R 29 ,R 30 ,R 31 ,R 32 ,R 33 ,R 41 ,R 44 ,R 45 ,R 46 ,R 48 ,R 50 ,R 51 ,R 58 ,R 6 3 ,R 64 ,R 65 ,R 66 ,R 70 ,R 71 are independently N or absent;
  • R 13 ,R 17 ,R 23 ,R 61 are independently A,C,U or absent;
  • R 10 ,R 14 ,R 24 ,R 40 ,R 52 ,R 56 are independently A,G or absent;
  • R 7 ,R 15 ,R 25 ,R 67 ,R 72 are independently A,G,U or absent;
  • R 11 ,R 57 are independently A,U or absent;
  • R 39 C,G or absent
  • R 3 ,R 4 ,R 22 ,R 42 ,R 49 ,R 55 ,R 62 are independently C,G,U or absent;
  • R 18 ,R 28 ,R 35 ,R 37 ,R 53 ,R 59 ,R 60 are independently C,U or absent;
  • R 19 G or absent
  • R 8 ,R 36 ,R 38 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II GLU (SEQ ID NO: 581),
  • R 0 ,R 18 ,R 23 are absent
  • R 17 ,R 40 are independently A or absent
  • R 26 ,R 27 ,R 34 ,R 43 ,R 68 ,R 69 ,R 71 are independently A,C,G or absent;
  • R 1 ,R 2 ,R 5 ,R 12 ,R 21 ,R 31 ,R 33 ,R 41 ,R 45 ,R 48 ,R 51 ,R 58 ,R 66 ,R 70 are independently N or absent;
  • R 44 ,R 61 are independently A,C,U or absent;
  • R 9 ,R 14 ,R 24 ,R 25 ,R 52 ,R 56 ,R 63 are independently A,G or absent;
  • R 7 ,R 15 ,R 46 ,R 50 ,R 67 ,R 72 are independently A,G,U or absent;
  • R 29 ,R 57 are independently A,U or absent;
  • R 60 C or absent
  • R 39 C,G or absent
  • R 3 ,R 6 ,R 20 ,R 30 ,R 32 ,R 42 ,R 55 ,R 62 ,R 65 are independently C,G,U or absent;
  • R 4 ,R 8 ,R 16 ,R 28 ,R 35 ,R 37 ,R 49 ,R 53 ,R 59 are independently C,U or absent;
  • R 10 ,Ri9 are independently G or absent;
  • R 22 ,R 64 are independently G,U or absent;
  • R 11 ,R 13 ,R 36 ,R 38 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III GLU (SEQ ID NO: 582),
  • R 14 ,R 27 ,R 40 ,R 71 are independently A or absent;
  • R 1 ,R 31 ,R 33 ,R 45 ,R 51 ,R 66 are independently N or absent;
  • R 21 ,R 41 are independently A,C,U or absent;
  • R 7 ,R 24 ,R 25 ,R 50 ,R 52 ,R 56 ,R 63 ,R 68 ,R 70 are independently A,G or absent;
  • R 5 ,R 46 are independently A,G,U or absent
  • R 29 ,R 57 ,R 67 ,R 72 are independently A,U or absent
  • R 2 ,R 39 ,R 60 are independently C or absent;
  • R 3 ,R 12 ,R 20 ,R 26 ,R 34 ,R 69 are independently C,G or absent;
  • R 6 ,R 30 ,R 42 ,R 48 ,R 65 are independently C,G,U o rabsent;
  • R 4 ,R 16 ,R 28 ,R 35 ,R 37 ,R 49 ,R 53 ,R 55 ,R 58 ,R 61 ,R 62 are independently C,U or absent;
  • R 9 ,R 10 ,R 19 ,R 64 are independently G or absent;
  • R 15 ,R 22 ,R 32 are independently G,U or absent;
  • R 8 ,R 11 ,R 13 ,R 36 ,R 38 ,R 54 ,R 59 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I GLY (SEQ ID NO: 583),
  • R 3 ,R 9 ,R 40 ,R 50 ,R 51 are independently A,C,G or absent;
  • R 4 ,R 5 ,R 6 ,R 7 ,R 12 ,R 16 ,R 21 ,R 22 ,R 26 ,R 29 ,R 30 ,R 31 ,R 32 ,R 33 ,R 34 ,R 41 ,R 42 , R 43 , R 44 ,R 45 ,R 46 , R 48 , R 49 , R 58 ,R 6 3 ,R 64 ,R 65 ,R 66 ,R 67 ,R 68 are independently N or absent;
  • R 59 A,C,U or absent
  • R 1 ,R 10 ,R 14 ,R 15 ,R 27 ,R 56 are independently A,G or absent;
  • R 20 ,R 25 are independently A,G,U or absent;
  • R 57 ,R 72 are independently A,U or absent;
  • R 38 ,R 39 ,R 60 are independently C or absent;
  • R 52 C,G or absent
  • R 2 ,R 19 ,R 37 ,R 54 ,R 55 ,R 61 ,R 62 ,R 69 ,R 70 are independently C,G,U or absent;
  • R 11 ,R 13 ,R 17 ,R 28 ,R 35 ,R 36 ,R 71 are independently C,U or absent;
  • R 8 ,R 18 ,R 23 ,R 53 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II GLY (SEQ ID NO: 584),
  • R 24 ,R 27 ,R 40 ,R 72 are independently A or absent;
  • R 26 A,C or absent;
  • R 3 ,R 7 ,R 68 are independently A,C,G or absent;
  • R 5 ,R 30 ,R 41 ,R 42 ,R 44 ,R 49 ,R 67 are independently A,C,G,U or absent;
  • R 31 ,R 32 ,R34 are independently A,C,U or absent;
  • R 9 ,R 10 ,R 14 ,R 15 ,R 33 ,R 50 ,R 56 are independently A,G or absent;
  • R 12 ,R 16 ,R 22 ,R 25 ,R 29 ,R 46 are independently A,G,U or absent;
  • R 57 A,U or absent;
  • R 17 ,R 38 ,R 39 ,R 60 ,R 61 ,R 71 are independently C or absent;
  • R 6 ,R 52 ,R 64 ,R 66 are independently C,G or absent;
  • R 2 ,R 4 ,R 37 ,R 48 ,R 55 ,R 65 are independently C,G,U or absent;
  • R 13 ,R 35 ,R 43 ,R 62 ,R 69 are independently C,U or absent;
  • R 1 ,R 19 ,R 20 ,R 51 ,R 70 are independently G or absent;
  • R 21 ,R 45 ,R 63 are independently G,U or absent;
  • R 8 ,R 11 ,R 28 ,R 36 ,R 53 ,R 54 ,R 58 ,R 59 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III GLY (SEQ ID NO: 585),
  • R 24 ,R 27 ,R 40 ,R 72 are independently A or absent;
  • R 26 A,C or absent;
  • R 3 ,R 7 ,R 49 ,R 68 are independently A,C,G or absent;
  • R 5 ,R 30 ,R 41 ,R 44 ,R 67 are independently N or absent;
  • R 31 ,R 32 ,R34 are independently A,C,U or absent;
  • R 9 ,R 10 ,R 14 ,R 15 ,R 33 ,R 50 ,R 56 are independently A,G or absent;
  • R 12 ,R 25 ,R 29 ,R 42 ,R 46 are independently A,G,U or absent;
  • R 16 ,R 57 are independently A,U or absent;
  • R 17 ,R 38 ,R 39 ,R 60 ,R 61 ,R 71 are independently C or absent;
  • R 6 ,R 52 ,R 64 ,R 66 are independently C,G or absent;
  • R 37 ,R 48 ,R 65 are independently C,G,U or absent;
  • R 2 ,R 4 ,R 13 ,R 35 ,R 43 ,R 55 ,R 62 ,R 69 are independently C,U or absent;
  • R 1 ,R 19 ,R 20 ,R 51 ,R 70 are independently G or absent;
  • R 21 ,R 22 ,R 45 ,R 63 are independently G,U or absent;
  • R 8 ,R 11 ,R 28 ,R 36 ,R 53 ,R 54 ,R 58 ,R 59 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I HIS (SEQ ID NO: 586),
  • R 14 ,R 24 ,R 57 are independently A or absent;
  • R 72 A,C or absent
  • R 9 ,R 27 ,R 43 ,R 48 ,R 69 are independently A,C,G or absent;
  • R 3 ,R 4 , R 5 ,R 6 ,R 12 ,R 25 ,R 26 ,R 29 ,R 30 ,R 31 ,R 34 ,R 42 ,R 45 ,R 46 , R 49 ,R 50 ,R 58 ,R 62 ,R 63 ,R 66 ,R 67 ,R 68 are independently N or absent;
  • R 13 ,R 21 ,R 41 ,R 44 ,R 65 are independently A,C,U or absent;
  • R 40 ,R 51 ,R 56 ,R 70 are independently A,G or absent;
  • R 7 ,R 32 are independently A,G,U or absent;
  • R 55 ,R 60 are independently C or absent;
  • R 11 ,R 16 ,R 33 ,R 64 are independently C,G,U or absent;
  • R 2 ,R 17 ,R 22 ,R 28 ,R 35 ,R 53 ,R 59 ,R 61 ,R 71 are independently C,U or absent;
  • R 1 ,R 10 ,R 15 ,R 19 ,R 20 ,R 37 ,R 39 ,R 52 are independently G or absent;
  • R 0 G,U or absent
  • R 8 ,R 18 ,R 36 ,R 38 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II HIS (SEQ ID NO: 587),
  • R 0 R 17 ,R 18 R 23 are absent;
  • R 7 ,R 12 ,R 14 ,R 24 ,R 27 ,R 45 ,R 57 ,R 58 ,R 63 ,R 67 ,R 72 are independently A or absent;
  • R3 A,C,U or absent
  • R 4 ,R 43 ,R 56 ,R 70 are independently A,G or absent
  • R 49 A,U or absent
  • R 2 ,R 28 ,R 30 ,R 41 ,R 42 ,R 44 ,R 48 ,R 55 ,R 60 ,R 66 ,R 71 are independently C or absent;
  • R 25 C,G or absent
  • R9 C,G,U or absent
  • R 8 ,R 13 ,R 26 ,R 33 ,R 35 ,R 50 ,R 53 ,R 61 ,R 68 are independently C,U or absent
  • R 1 ,R 6 ,R 10 ,R 15 ,R 19 ,R 20 ,R 32 ,R 34 ,R 37 ,R 39 ,R 40 ,R 46 ,R 51 ,R 52 ,R 62 ,R 64 ,R 69 are independently G or absent;
  • R 16 G,U or absent
  • R 5 ,R 11 ,R 21 ,R 22 ,R 29 ,R 31 ,R 36 ,R 38 ,R 54 ,R 59 ,R 65 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III HIS (SEQ ID NO: 588),
  • R 0 ,R 17 ,R 18 R 23 are absent
  • R 7 ,R 12 ,R 14 ,R 24 ,R 27 ,R 45 ,R 57 ,R 58 ,R 63 ,R 67 ,R 72 are independently A or absent;
  • R 3 A,C or absent
  • R 4 ,R 43 ,R 56 ,R 70 are independently A,G or absent
  • R 49 A,U or absent
  • R 2 ,R 28 ,R 30 ,R 41 ,R 42 ,R 44 ,R 48 ,R 55 ,R 60 ,R 66 ,R 71 are independently C or absent;
  • R 8 ,R 9 ,R 26 ,R 33 ,R 35 ,R 50 ,R 61 ,R 68 are independently C,U or absent;
  • R 1 ,R 6 ,R 10 ,R 15 ,R 19 ,R 20 ,R 25 ,R 32 ,R 34 ,R 37 ,R 39 ,R 40 ,R 46 ,R 51 ,R 52 ,R 62 ,R 64 ,R 69 are independently G or absent;
  • R 5 ,R 11 ,R 13 ,R 16 ,R 21 ,R 22 ,R 29 ,R 31 ,R 36 ,R 38 ,R 53 ,R 54 ,R 59 ,R 65 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I ILE (SEQ ID NO: 589),
  • R 38 ,R 41 ,R 57 ,R 72 are independently A or absent;
  • R 1 ,R 26 are independently A,C,G or absent;
  • R 18 ,R 54 are independently A,U or absent;
  • R 60 C or absent
  • R 2 ,R 52 ,R 70 are independently C,G or absent;
  • R 5 ,R 12 ,R 21 ,R 30 ,R 33 ,R 71 are independently C,G,U or absent;
  • R 11 ,R 13 ,R 17 ,R 28 ,R 35 ,R 53 ,R 55 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 are independently G or absent;
  • R 8 ,R 36 ,R 39 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II ILE (SEQ ID NO: 590),
  • R 24 ,R 38 ,R 40 ,R 41 ,R 57 ,R 72 are independently A or absent;
  • R 26 ,R 65 are independently A,C or absent;
  • R 58 ,R 59 ,R 67 are independently N or absent;
  • R 22 A,C,U or absent
  • R 6 ,R 9 ,R 14 ,R 15 ,R 29 ,R 34 ,R 43 ,R 46 ,R 48 ,R 50 ,R 51 ,R 63 ,R 69 are independently A,G or absent
  • R 37 ,R 56 are independently A,G,U or absent;
  • R 54 A,U or absent
  • R 28 ,R 35 ,R 60 ,R 62 ,R 71 are independently C or absent
  • R 2 ,R 52 ,R 70 are independently C,G or absent;
  • R 5 C,G,U or absent
  • R 3 ,R 4 ,R 11 ,R 13 ,R 17 ,R 21 ,R 30 ,R 42 ,R 44 ,R 45 ,R 49 ,R 53 ,R 55 ,R 61 ,R 64 ,R 66 are independently C,U or absent;
  • R 1 ,R 10 ,R 19 ,R 20 ,R 25 ,R 27 ,R 31 ,R 68 are independently G or absent;
  • R 7 ,R 12 ,R 32 are independently G,U or absent;
  • R 8 ,R 16 ,R 33 ,R 36 ,R 39 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III ILE (SEQ ID NO: 591),
  • R 14 ,R 24 ,R 38 ,R 40 ,R 41 ,R 57 ,R 72 are independently A or absent;
  • R 26 ,R 65 are independently A,C or absent;
  • R 22 ,R 59 are independently A,C,U or absent;
  • R 6 ,R 9 ,R 15 ,R 34 ,R 43 ,R 46 ,R 51 ,R 56 ,R 63 ,R 69 are independently A,G or absent;
  • R 37 A,G,U or absent
  • R 13 ,R 28 ,R 35 ,R 44 ,R 55 ,R 60 ,R 62 ,R 71 are independently C or absent;
  • R 2 ,R 5 ,R 70 are independently C,G or absent;
  • R 58 ,R 67 are independently C,G,U or absent;
  • R 3 ,R 4 ,R 11 ,R 17 ,R 21 ,R 30 ,R 42 ,R 45 ,R 49 ,R 53 ,R 61 ,R 64 ,R 66 are independently C,U or absent;
  • R 1 ,R 10 ,R 19 ,R 20 ,R 25 ,R 27 ,R 29 ,R 31 ,R 32 ,R 48 ,R 50 ,R 52 ,R 68 are independently G or absent;
  • R 7 ,Ri2 are independently G,U or absent;
  • R 8 ,R 16 ,R 33 ,R 36 ,R 39 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I MET (SEQ ID NO: 592),
  • R 14 ,R 38 ,R 40 ,R 57 are independently A or absent;
  • R 60 A,C or absent;
  • R 33 ,R 48 ,R 70 are independently A,C,G or absent;
  • R 1 ,R 3 ,R 4 ,R 5 ,R 6 ,R 11 ,R 12 ,R 16 ,R 17 ,R 21 ,R 22 ,R 26 ,R 27 ,R 29 ,R 30 ,R 31 ,R 32 ,R 42 ,R 44 ,R 45 ,R 46 ,R 49 ,R 50 ,R 58 ,R 6 2,R 63 ,R 66 ,R 67 ,R 68 ,R 69 ,R 71 are independently N or absent;
  • R 18 ,R 35 ,R 41 ,R 59 ,R 65 are independently A,C,U or absent;
  • R 9 ,R 15 ,R 51 are independently A,G or absent;
  • R 7 ,R 24 ,R 25 ,R 34 ,R 53 ,R 56 are independently A,G,U or absent;
  • R 72 A,U or absent
  • R 37 C or absent
  • R 10 ,R 55 are independently C,G or absent
  • R 2 ,R 13 ,R 28 ,R 43 ,R 64 are independently C,G,U or absent;
  • R 36 ,R 61 are independently C,U or absent;
  • R 19 ,R 20 ,R 52 are independently G or absent;
  • R 8 ,R 39 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II MET (SEQ ID NO: 593),
  • R 14 ,R 24 ,R 38 ,R 40 ,R 41 ,R 57 ,R 72 are independently A or absent;
  • R 59 ,R 60 ,R 62 ,R 65 are independently A,C or absent;
  • R 6 ,R 45 ,R 67 are independently A,C,G or absent;
  • R4 N or absent
  • R 21 ,R 42 are independently A,C,U or absent
  • R 3 ,R 13 ,R 37 are independently C or absent;
  • R 48 ,R 55 ,R 64 ,R 70 are independently C,G or absent;
  • R 2 ,R 5 ,R 66 ,R 68 are independently C,G,U or absent;
  • R 11 ,R 16 ,R 26 ,R 28 ,R 30 ,R 31 ,R 35 ,R 36 ,R 43 ,R 44 ,R 61 ,R 71 are independently C,U or absent;
  • R 10 ,R 12 ,R 15 ,R 19 ,R 20 ,R 25 ,R 33 ,R 52 ,R 69 are independently G or absent;
  • R 7 ,R 34 ,R 50 are independently G,U or absent;
  • R 8 ,R 39 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III MET (SEQ ID NO: 594),
  • R 14 ,R 24 ,R 38 ,R 40 ,R 41 ,R 57 ,R 72 are independently A or absent;
  • R 59 ,R 62 ,R 65 are independently A,C or absent;
  • R 6 ,R 67 are independently A,C,G or absent;
  • R 4 ,R 21 are independently A,C,U or absent;
  • R 49 ,R 53 ,R 63 are independently A,U or absent;
  • R 3 ,R 13 ,R 26 ,R 37 ,R 43 ,R 60 are independently C or absent;
  • R 2 ,R 48 ,R 55 ,R 64 ,R 70 are independently C,G or absent;
  • R 5 ,R 66 are independently C,G,U or absent;
  • R 11 ,R 16 ,R 28 ,R 30 ,R 31 ,R 35 ,R 36 ,R 42 ,R 44 ,R 61 ,R 71 are independently C,U or absent;
  • R 10 ,R 12 ,R 15 ,R 19 ,R 20 ,R 25 ,R 33 ,R 52 ,R 69 are independently G or absent;
  • R 7 ,R 34 ,R 50 ,R 68 are independently G,U or absent;
  • R 8 ,R 39 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I LEU (SEQ ID NO: 595),
  • R 38 ,R 57 are independently A or absent;
  • R 60 A,C or absent
  • R 1 ,R 13 ,R 27 ,R 48 ,R 51 ,R 56 are independently A,C,G or absent;
  • R 24 ,R 40 are independently A,G,U or absent;
  • R 52 ,R 61 ,R 64 ,R 71 are independently C,G,U or absent;
  • R 36 ,R 53 ,R 59 are independently C,U or absent;
  • R 19 G or absent
  • R 20 G,U or absent
  • R 8 ,R 54 are independently U or absent
  • a TREM disclosed herein comprises the sequence of Formula II LEU (SEQ ID NO: 596),
  • R 38 ,R 57 ,R 72 are independently A or absent;
  • R 60 A,C or absent
  • R 4 ,R 5 ,R 48 ,R 50 ,R 56 ,R 69 are independently A,C,G or absent
  • R 6 ,R 33 ,R 41 ,R 43 ,R 46 ,R 49 ,R 58 ,R 63 ,R 66 ,R 70 are independently N or absent;
  • R 11 ,R 12 ,R 17 ,R 21 ,R 22 ,R 28 ,R 31 ,R 37 ,R 44 ,R 55 are independently A,C,U or absent;
  • R 1 ,R 9 ,R 14 ,R 15 ,R 24 ,R 27 ,R 34 ,R 39 are independently A,G or absent;
  • R 7 ,R 29 ,R 32 ,R 40 ,R 45 are independently A,G,U or absent;
  • R 25 A,U or absent
  • R 13 C,G or absent
  • R 2 ,R 3 ,R 16 ,R 26 ,R 30 ,R 52 ,R 62 ,R 64 ,R 65 ,R 67 ,R 68 are independently C,G,U or absent;
  • R 10 ,R 20 are independently G,U or absent;
  • R 8 ,R 23 ,R 36 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III LEU (SEQ ID NO: 597),
  • R 38 ,R 57 ,R 72 are independently A or absent;
  • R 60 A,C or absent;
  • R 4 ,R 5 ,R 48 ,R 50 ,R 56 ,R 58 ,R 69 are independently A,C,G or absent;
  • R 6 ,R 33 ,R 43 ,R 46 ,R 49 ,R 63 ,R 66 ,R 70 are independently N or absent;
  • R 11 ,R 12 ,R 17 ,R 21 ,R 22 ,R 28 ,R 31 ,R 37 ,R 41 ,R 44 ,R 55 are independently A,C,U or absent;
  • R 1 ,R 9 ,R 14 ,R 15 ,R 24 ,R 27 ,R 34 ,R 39 are independently A,G or absent;
  • R 7 ,R 29 ,R 32 ,R 40 ,R 45 are independently A,G,U or absent;
  • R 25 A,U or absent
  • R 13 C,G or absent
  • R 2 ,R 3 ,R 16 ,R 30 ,R 52 ,R 62 ,R 64 ,R 67 ,R 68 are independently C,G,U or absent;
  • R 10 ,R 20 ,R 26 are independently G,U or absent;
  • R 8 ,R 23 ,R 36 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I LYS (SEQ ID NO: 598),
  • R 14 A or absent;
  • R 40 ,R 41 are independently A,C or absent;
  • R 34 ,R 43 ,R 51 are independently A,C,G or absent;
  • R 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 6 ,R 7 ,R 11 ,R 12 ,R 16 ,R 21 ,R 26 ,R 30 ,R 31 ,R 32 ,R 44 ,R 45 ,R 46 ,R 48 ,R 49 ,R 50 ,R 58 ,R 62 ,R 63 ,R 65 , R 66 ,R 67 ,R 68 ,R 69 ,R 70 are independently N or absent;
  • R 13 ,R 17 ,R 59 ,R 71 are independently A,C,U or absent;
  • R 9 ,R 15 ,R 19 ,R 20 ,R 25 ,R 27 ,R 52 ,R 56 are independently A,G or absent;
  • R 24 ,R 29 ,R 72 are independently A,G,U or absent;
  • R 18 ,R 57 are independently A,U or absent;
  • R 10 ,R 33 are independently C,G or absent;
  • R 42 ,R 61 ,R 64 are independently C,G,U or absent;
  • R 28 ,R 35 ,R 36 ,R 37 ,R 53 ,R 55 ,R 60 are independently C,U or absent;
  • R 8 ,R 22 ,R 23 ,R 38 ,R 39 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II LYS (SEQ ID NO: 599),
  • R 14 A or absent;
  • R 40 ,R 41 ,R 43 are independently A,C or absent;
  • R 3 ,R 7 are independently A,C,G or absent;
  • R 1 ,R 6 ,R 11 ,R 31 ,R 45 ,R 48 ,R 49 ,R 63 ,R 65 ,R 66 ,R 68 are independently N or absent;
  • R 2 ,R 12 ,R 13 ,R 17 ,R 44 ,R 67 ,R 71 are independently A,C,U or absent;
  • R 9 ,R 15 ,R 19 ,R 20 ,R 25 ,R 27 ,R 34 ,R 50 ,R 52 ,R 56 ,R 70 ,R 72 are independently A,G or absent;
  • R 5 ,R 24 ,R 26 ,R 29 ,R 32 ,R 46 ,R 69 are independently A,G,U or absent;
  • R 57 A,U or absent;
  • R 10 ,R 61 are independently C,G or absent;
  • R 4 ,R 16 ,R 21 ,R 30 ,R 58 ,R 64 are independently C,G,U or absent;
  • R 28 ,R 35 ,R 36 ,R 37 ,R 42 ,R 53 ,R 55 ,R 59 ,R 60 ,R 62 are independently C,U or absent;
  • R 33 ,R 51 are independently G or absent;
  • R 22 ,R 38 ,R 39 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III LYS (SEQ ID NO: 600),
  • R 40 A,C or absent
  • R 1 ,R 3 ,R 7 ,R3i are independently A,C,G or absent;
  • R 48 ,R 65 ,R 68 are independently N or absent;
  • R 2 ,R 13 ,R 17 ,R 44 ,R 63 ,R 66 are independently A,C,U or absent;
  • R 5 ,R 15 ,R 19 ,R 20 ,R 25 ,R 27 ,R 29 ,R 50 ,R 52 ,R 56 ,R 70 ,R 72 are independently A,G or absent;
  • R 6 ,R 24 ,R 32 ,R 49 are independently A,G,U or absent;
  • R 12 ,R 26 ,R 46 ,R 57 are independently A,U or absent;
  • R 11 ,R 28 ,R 35 ,R 43 are independently C or absent;
  • R 10 ,R 45 ,R 61 are independently C,G or absent;
  • R 4 ,R 21 ,R 64 are independently C,G,U or absent;
  • R 37 ,R 53 ,R 55 ,R 59 ,R 60 ,R 62 ,R 67 ,R 71 are independently C,U or absent;
  • R 33 ,R 51 are independently G or absent;
  • R 8 ,R 30 ,R 58 ,R 69 are independently G,U or absent;
  • R 16 ,R 22 ,R 36 ,R 38 ,R 39 ,R 42 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I PHE (SEQ ID NO: 601),
  • R 0 ,R 23 are absent
  • R 9 ,R 14 ,R 38 ,R 39 ,R 57 ,R 72 are independently A or absent
  • R 71 A,C or absent
  • R 41 ,R 70 are independently A,C,G or absent;
  • R 4 ,R 5 ,R 6 ,R 30 ,R 31 ,R 32 ,R 34 , R 42 , R 44 , R 45 , R 46 , R 48 ,R 49 ,R 58 ,R 62 ,R 63 ,R 66 ,R 67 ,R 68 ,R 69 are independently N or absent;
  • R 2 ,R 3 ,R 21 ,R 33 ,R 43 ,R 50 ,R 64 are independently C,G,U or absent;
  • R 11 ,R 12 ,R 13 ,R 17 ,R 28 ,R 35 ,R 36 ,R 59 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 ,R 25 ,R 37 ,R 52 are independently G or absent;
  • R 8 ,R 18 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula II PHE (SEQ ID NO: 602),
  • R 14 ,R 24 ,R 38 ,R 39 ,R 57 ,R 72 are independently A or absent;
  • R 46 ,R 71 are independently A,C or absent;
  • R 4 ,R 70 are independently A,C,G or absent;
  • R 45 A,C,U or absent;
  • R 6 ,R 7 ,R 15 ,R 26 ,R 27 ,R 32 ,R 34 ,R 40 ,R 41 ,R 56 ,R 69 are independently A,G or absent;
  • R 29 A,G,U or absent;
  • R 5 ,R 9 ,R 67 are independently A,U or absent;
  • R 35 ,R 49 ,R 55 ,R 60 are independently C or absent;
  • R 21 ,R 43 ,R 62 are independently C,G or absent;
  • R 2 ,R 33 ,R 68 are independently C,G,U or absent;
  • R 3 ,R 11 ,R 12 ,R 13 ,R 28 ,R 30 ,R 36 ,R 42 ,R 44 ,R 48 ,R 58 ,R 59 ,R 61 ,R 66 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 ,R 25 ,R 37 ,R 51 ,R 52 ,R 63 ,R 64 are independently G or absent;
  • R 1 ,R 31 ,R 50 are independently G,U or absent;
  • R 8 ,R 16 ,R 17 ,R 22 ,R 53 ,R 54 ,R 65 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III PHE (SEQ ID NO: 603),
  • R 5 ,R 7 ,R 14 ,R 24 ,R 26 ,R 32 ,R 34 ,R 38 ,R 39 ,R 41 ,R 57 ,R 72 are independently A or absent;
  • R 46 A,C or absent;
  • R 70 A,C,G or absent;
  • R 4 ,R 6 ,R 15 ,R 56 ,R 69 are independently A,G or absent;
  • R 9 ,R 45 are independently A,U or absent;
  • R 2 ,R 11 ,R 13 ,R 35 ,R 43 ,R 49 ,R 55 ,R 60 ,R 68 ,R 71 are independently C or absent;
  • R 33 C,G or absent;
  • R 3 ,R 28 ,R 36 ,R 48 ,R 58 ,R 59 ,R 61 are independently C,U or absent;
  • R 1 ,R 10 ,R 19 ,R 20 ,R 21 ,R 25 ,R 27 ,R 29 ,R 37 ,R 40 ,R 51 ,R 52 ,R 62 ,R 63 ,R 64 are independently G or absent;
  • R 8 ,R 12 ,R 16 ,R 17 ,R 30 ,R 31 ,R 42 ,R 44 ,R 50 ,R 53 ,R 54 ,R 65 ,R 66 ,R 67 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I PRO (SEQ ID NO: 604),
  • R 14 ,R 57 are independently A or absent;
  • R 70 ,R 72 are independently A,C or absent;
  • R 9 ,R 26 ,R 27 are independently A,C,G or absent;
  • R 4 ,R 5 ,R 6 ,R 16 ,R 21 ,R 29 ,R 30 ,R 31 ,R 32 ,R 33 ,R 34 ,R 37 ,R 41 ,R 42 , R 43 , R 44 , R 45 , R 46 , R 48 , R 49 , R 50 ,R 58 ,R 61 ,R 62 , R 63 ,R 64 ,R 66 ,R 67 ,R 68 are independently N or absent;
  • R 35 ,R 65 are independently A,C,U or absent;
  • R 24 ,R 40 ,R 56 are independently A,G or absent;
  • R 7 ,R 25 ,R 51 are independently A,G,U or absent;
  • R 55 ,R 60 are independently C or absent;
  • R 1 ,R 3 ,R 71 are independently C,G or absent;
  • R 11 ,R 12 ,R 20 ,R 69 are independently C,G,U or absent;
  • R 13 ,R 17 ,R 18 ,R 22 ,R 23 ,R 28 ,R 59 are independently C,U or absent;
  • R 10 ,R 15 ,R 19 ,R 38 ,R 39 ,R 52 are independently G or absent;
  • R 2 are independently G,U or absent
  • R 8 ,R 36 ,R 53 ,R 54 are independently U or absent;
  • R 14 ,R 45 ,R 56 ,R 57 ,R 58 ,R 65 ,R 68 are independently A or absent;
  • R 61 A,C,G or absent;
  • R 43 N or absent;
  • R 37 A, C,U or absent
  • R 24 ,R 27 ,R 33 ,R 40 ,R 44 ,R 63 are independently A,G or absent;
  • R 3 ,R 12 ,R 30 ,R 32 ,R 48 ,R 55 ,R 60 ,R 70 ,R 71 ,R 72 are independently C or absent;
  • R 5 ,R 34 ,R 42 ,R 66 are independently C,G or absent;
  • R 20 C,G,U or absent;
  • R 35 ,R 41 ,R 49 ,R 62 are independently C,U or absent;
  • R 1 ,R 2 ,R 6 ,R 9 ,R 10 ,R 15 ,R 19 ,R 26 ,R 38 ,R 39 ,R 46 ,R 50 ,R 51 ,R 52 ,R 64 ,R 67 ,R 69 are independently G or absent;
  • R 11 ,Ri6 are independently G,U or absent;
  • R 4 ,R 7 ,R 8 ,R 13 ,R 21 ,R 25 ,R 28 ,R 29 ,R 31 ,R 36 ,R 53 ,R 54 ,R 59 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III PRO (SEQ ID NO: 606),
  • R 14 ,R 45 ,R 56 ,R 57 ,R 58 ,R 65 ,R 68 are independently A or absent;
  • R 37 A,C,U or absent
  • R 24 ,R 27 ,R 40 are independently A,G or absent;
  • R 3 ,R 5 ,R 12 ,R 30 ,R 32 ,R 48 ,R 49 ,R 55 ,R 60 ,R 61 ,R 62 ,R 66 ,R 70 ,R 71 ,R 72 are independently C or absent;
  • R 34 ,R 42 are independently C,G or absent;
  • R 43 C,G,U or absent;
  • R 41 C,U or absent
  • R 1 ,R 2 ,R 6 ,R 9 ,R 10 ,Rl 5 ,R 19 ,R 20 ,R 26 ,R 33 ,R 38 ,R 39 ,R 44 ,R 46 ,R 50 ,R 51 ,R 52 ,R 63 ,R 64 ,R 67 ,R 69 are independently G or absent;
  • R 16 G,U or absent;
  • R 4 ,R 7 ,R 8 ,R 11 ,R 13 ,R 21 ,R 25 ,R 28 ,R 29 ,R 31 ,R 35 ,R 36 ,R 53 ,R 54 ,R 59 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula I SER (SEQ ID NO: 607),
  • R 14 ,R 24 ,R 57 are independently A or absent;
  • R 41 A,C or absent
  • R 2 , R 3 , R 4 , R 5 ,R 6 ,R 7 ,R 9 ,R 10 ,R 11 ,R 12 ,R 13 ,R 16 ,R 21 ,R 25 ,R 26 ,R 27 ,R 28 ,R 30 ,R 31 ,R 32 ,R 33 ,R 34 ,R 37 , R 42 , R 43 , R 44 ,R 45 , R 46 , R 48 , R 49 ,R 50 ,R 62 ,R 63 ,R 64 ,R 65 ,R 66 ,R 67 ,R 68 ,R 69 ,R 70 are independently N or absent;
  • R 18 A,C,U or absent;
  • R 15 ,R 40 ,R 51 ,R 56 are independently A,G or absent;
  • R 1 ,R 29 ,R 58 ,R 72 are independently A,G,U or absent;
  • R 39 A,U or absent
  • R 60 C or absent
  • R 38 C,G or absent
  • R 17 ,R 22 ,R 23 ,R 71 are independently C,G,U or absent
  • R 8 ,R 35 ,R 36 ,R 55 ,R 59 ,R 61 are independently C,U or absent;
  • R 19 ,R 20 are independently G or absent;
  • R 52 G,U or absent
  • R 53 ,R 54 are independently U or absent
  • a TREM disclosed herein comprises the sequence of Formula II SER (SEQ ID NO: 608),
  • R 14 ,R 24 ,R 41 ,R 57 are independently A or absent;
  • R 44 A,C or absent
  • R 25 ,R 45 ,R 48 are independently A,C,G or absent
  • R 2 ,R 3 ,R 4 ,R 5 ,R 37 ,R 50 ,R 62 ,R 66 ,R 67 ,R 69 ,R 70 are independently N or absent;
  • R 12 ,R 28 ,R 65 are independently A,C,U or absent;
  • R 9 ,R 15 ,R 29 ,R 34 ,R 40 ,R 56 ,R 63 are independently A,G or absent;
  • R 7 ,R 26 ,R 30 ,R 33 ,R 46 ,R 58 ,R 72 are independently A,G,U or absent;
  • R 39 A,U or absent
  • R 11 ,R 35 ,R 60 ,R 61 are independently C or absent;
  • R 13 ,R 38 are independently C,G or absent;
  • R 6 ,R 17 ,R 31 ,R 43 ,R 64 ,R 68 are independently C,G,U or absent;
  • R 36 ,R 42 ,R 49 ,R 55 ,R 59 ,R 71 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 ,R 27 ,R 51 are independently G or absent;
  • R 1 ,R 16 ,R 32 ,R 52 are independently G,U or absent;
  • R 8 ,R 18 ,R 21 ,R 22 ,R 53 ,R 54 are independently U or absent;
  • a TREM disclosed herein comprises the sequence of Formula III SER (SEQ ID NO: 609),
  • R 14 ,R 24 ,R 41 ,R 57 ,R 58 are independently A or absent;
  • R 44 A,C or absent
  • R 25 ,R 48 are independently A,C,G or absent
  • R 2 ,R 3 ,R 5 ,R 37 ,R 66 ,R 67 ,R 69 ,R 70 are independently N or absent;
  • R 12 ,R 28 ,R 62 are independently A,C,U or absent;
  • R 7 ,R 9 ,R 15 ,R 29 ,R 33 ,R 34 ,R 40 ,R 45 ,R 56 ,R 63 are independently A,G or absent;
  • R 4 ,R 26 ,R 46 ,R 50 are independently A,G,U or absent;
  • R 30 ,R 39 are independently A,U or absent;
  • R 11 ,R 17 ,R 35 ,R 60 ,R 61 are independently C or absent;
  • R 13 ,R 3 8 are independently C,G or absent;
  • R 6 ,R 64 are independently C,G,U or absent;
  • R 31 ,R 42 ,R 43 ,R 49 ,R 55 ,R 59 ,R 65 ,R 68 ,R 71 are independently C,U or absent;
  • R 10 ,R 19 ,R 20 ,R 27 ,R 51 ,R 52 are independently G or absent;
  • R 1 ,R 16 ,R 32 ,R 72 are independently G,U or absent;
  • R 8 ,R 18 ,R 21 ,R 22 ,R 36 ,R 53 ,R 54 are independently U or absent;

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2021/065159 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof Ceased WO2022140702A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2021409740A AU2021409740A1 (en) 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof
CA3206285A CA3206285A1 (en) 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof
BR112023012377A BR112023012377A2 (pt) 2020-12-23 2021-12-23 Composições de trems modificadas e usos das mesmas
US18/269,450 US20240175020A1 (en) 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof
MX2023007630A MX2023007630A (es) 2020-12-23 2021-12-23 Composiciones de trem modificadas y usos de las mismas.
KR1020237025192A KR20230135585A (ko) 2020-12-23 2021-12-23 변형된 trem의 조성물 및 이의 용도
JP2023538736A JP2024501288A (ja) 2020-12-23 2021-12-23 修飾ｔｒｅｍの組成物及びその使用
CN202180094267.XA CN117083383A (zh) 2020-12-23 2021-12-23 经修饰的trem的组合物及其用途
IL303886A IL303886A (en) 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof
EP21854913.7A EP4267732A1 (en) 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063130381P 2020-12-23 2020-12-23
US202063130377P 2020-12-23 2020-12-23
US202063130387P 2020-12-23 2020-12-23
US202063130374P 2020-12-23 2020-12-23
US202063130373P 2020-12-23 2020-12-23
US202063130375P 2020-12-23 2020-12-23
US63/130,375 2020-12-23
US63/130,373 2020-12-23
US63/130,377 2020-12-23
US63/130,374 2020-12-23
US63/130,381 2020-12-23
US63/130,387 2020-12-23

Publications (1)

Publication Number Publication Date
WO2022140702A1 true WO2022140702A1 (en) 2022-06-30

Family

ID=80445752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/065159 Ceased WO2022140702A1 (en) 2020-12-23 2021-12-23 Compositions of modified trems and uses thereof

Country Status (11)

Country Link
US (1) US20240175020A1 (enExample)
EP (1) EP4267732A1 (enExample)
JP (1) JP2024501288A (enExample)
KR (1) KR20230135585A (enExample)
AU (1) AU2021409740A1 (enExample)
BR (1) BR112023012377A2 (enExample)
CA (1) CA3206285A1 (enExample)
IL (1) IL303886A (enExample)
MX (1) MX2023007630A (enExample)
TW (1) TW202242108A (enExample)
WO (1) WO2022140702A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023064513A3 (en) * 2021-10-13 2023-06-15 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use
WO2023250112A1 (en) * 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024216191A1 (en) * 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
WO2025196508A1 (en) * 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Targeted delivery of therapeutic agents to hepatocytes

Citations (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US99823A (en) 1870-02-15 Improved indigo soap
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4845205A (en) 1985-01-08 1989-07-04 Institut Pasteur 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites
US4981957A (en) 1984-07-19 1991-01-01 Centre National De La Recherche Scientifique Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5177195A (en) 1991-01-08 1993-01-05 Imperial Chemical Industries Plc Disazo dyes
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5319080A (en) 1991-10-17 1994-06-07 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5405939A (en) 1987-10-22 1995-04-11 Temple University Of The Commonwealth System Of Higher Education 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5446137A (en) 1993-12-09 1995-08-29 Syntex (U.S.A.) Inc. Oligonucleotides containing 4'-substituted nucleotides
US5455233A (en) 1989-11-30 1995-10-03 University Of North Carolina Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5466677A (en) 1993-03-06 1995-11-14 Ciba-Geigy Corporation Dinucleoside phosphinates and their pharmaceutical compositions
US5466786A (en) 1989-10-24 1995-11-14 Gilead Sciences 2'modified nucleoside and nucleotide compounds
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5514785A (en) 1990-05-11 1996-05-07 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5519126A (en) 1988-03-25 1996-05-21 University Of Virginia Alumni Patents Foundation Oligonucleotide N-alkylphosphoramidates
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5541316A (en) 1992-02-11 1996-07-30 Henkel Kommanditgesellschaft Auf Aktien Process for the production of polysaccharide-based polycarboxylates
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5552540A (en) 1987-06-24 1996-09-03 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5567811A (en) 1990-05-03 1996-10-22 Amersham International Plc Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5576427A (en) 1993-03-30 1996-11-19 Sterling Winthrop, Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5610300A (en) 1992-07-01 1997-03-11 Ciba-Geigy Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5639873A (en) 1992-02-05 1997-06-17 Centre National De La Recherche Scientifique (Cnrs) Oligothionucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5658873A (en) 1993-04-10 1997-08-19 Degussa Aktiengesellschaft Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them
US5663312A (en) 1993-03-31 1997-09-02 Sanofi Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5677439A (en) 1990-08-03 1997-10-14 Sanofi Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5750692A (en) 1990-01-11 1998-05-12 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US6028188A (en) 1993-11-16 2000-02-22 Genta Incorporated Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US6124445A (en) 1994-11-23 2000-09-26 Isis Pharmaceuticals, Inc. Phosphotriester oligonucleotides, amidities and method of preparation
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6169170B1 (en) 1994-03-18 2001-01-02 Lynx Therapeutics, Inc. Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US6239265B1 (en) 1990-01-11 2001-05-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6326199B1 (en) 1991-12-24 2001-12-04 Isis Pharmaceuticals, Inc. Gapped 2′ modified oligonucleotides
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6534639B1 (en) 1999-07-07 2003-03-18 Isis Pharmaceuticals, Inc. Guanidinium functionalized oligonucleotides and method/synthesis
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6858715B2 (en) 1999-02-04 2005-02-22 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US20050175682A1 (en) 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20060008378A1 (en) 2004-04-30 2006-01-12 Kunihiro Imai Sterilization method
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
WO2006045116A2 (en) * 2004-10-20 2006-04-27 The Scripps Research Institute In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US7321029B2 (en) 2000-01-21 2008-01-22 Geron Corporation 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
US20080020058A1 (en) 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20080042973A1 (en) 2006-07-10 2008-02-21 Memsic, Inc. System for sensing yaw rate using a magnetic field sensor and portable electronic devices using the same
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20100062967A1 (en) 2004-12-27 2010-03-11 Silence Therapeutics Ag Coated lipid complexes and their use
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US20110076335A1 (en) 2009-07-01 2011-03-31 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US20110256175A1 (en) 2008-10-09 2011-10-20 The University Of British Columbia Amino lipids and methods for the delivery of nucleic acids
US8106022B2 (en) 2007-12-04 2012-01-31 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20120027796A1 (en) 2008-11-10 2012-02-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20120027803A1 (en) 2010-06-03 2012-02-02 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20120058144A1 (en) 2008-11-10 2012-03-08 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
WO2012030683A2 (en) 2010-08-31 2012-03-08 Merck Sharp & Dohme Corp. Novel single chemical entities and methods for delivery of oligonucleotides
US8158601B2 (en) 2009-06-10 2012-04-17 Alnylam Pharmaceuticals, Inc. Lipid formulation
US20120095200A1 (en) 2009-06-05 2012-04-19 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by nucleic acid containing a dicer substrate and a receptor binding region
US20120101478A1 (en) 2010-10-21 2012-04-26 Allergan, Inc. Dual Cartridge Mixer Syringe
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US20120128767A1 (en) 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
US20120149894A1 (en) 2009-08-20 2012-06-14 Mark Cameron Novel cationic lipids with various head groups for oligonucleotide delivery
US20120202871A1 (en) 2009-07-01 2012-08-09 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2012162210A1 (en) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Ring constrained cationic lipids for oligonucleotide delivery
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20130053572A1 (en) 2010-01-22 2013-02-28 Steven L. Colletti Novel Cationic Lipids for Oligonucleotide Delivery
US20130090372A1 (en) 2010-06-04 2013-04-11 Brian W. Budzik Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
US20130116307A1 (en) 2010-05-12 2013-05-09 Protiva Biotherapeutics Inc. Novel cyclic cationic lipids and methods of use
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US20130178541A1 (en) 2010-09-20 2013-07-11 Matthew G. Stanton Novel low molecular weight cationic lipids for oligonucleotide delivery
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
US20130195920A1 (en) 2011-12-07 2013-08-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
US20130274504A1 (en) 2010-10-21 2013-10-17 Steven L. Colletti Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery
US20130274523A1 (en) 2010-09-30 2013-10-17 John A. Bawiec, III Low molecular weight cationic lipids for oligonucleotide delivery
WO2013166155A1 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Novel tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
WO2013166121A1 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
US20130303587A1 (en) 2010-06-30 2013-11-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130338210A1 (en) 2009-12-07 2013-12-19 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20140039032A1 (en) 2011-12-12 2014-02-06 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising cationic lipid for drug delivery system
US20140200257A1 (en) 2011-01-11 2014-07-17 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2014136086A1 (en) 2013-03-08 2014-09-12 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20150005363A1 (en) 2011-12-07 2015-01-01 Alnylam Pharmaceuticals, Inc. Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
US20150057373A1 (en) 2012-03-27 2015-02-26 Sirna Therapeutics, Inc DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
US20150064242A1 (en) 2012-02-24 2015-03-05 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US20150140070A1 (en) 2013-10-22 2015-05-21 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
US20150141678A1 (en) 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
WO2015095340A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US20150203446A1 (en) 2011-09-27 2015-07-23 Takeda Pharmaceutical Company Limited Di-aliphatic substituted pegylated lipids
US20150239926A1 (en) 2013-11-18 2015-08-27 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for rna delivery
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US20150376115A1 (en) 2014-06-25 2015-12-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
US20160317458A1 (en) 2013-12-19 2016-11-03 Luis Brito Lipids and Lipid Compositions for the Delivery of Active Agents
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
US20160376224A1 (en) 2015-06-29 2016-12-29 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
US20170119904A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017083368A1 (en) 2015-11-12 2017-05-18 Pfizer Inc. Tissue-specific genome engineering using crispr-cas9
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9708628B2 (en) 2011-11-18 2017-07-18 Nof Corporation Cationic lipid having improved intracellular kinetics
WO2017123646A1 (en) 2016-01-11 2017-07-20 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cancer indications
US20170210967A1 (en) 2010-12-06 2017-07-27 Schlumberger Technology Corporation Compositions and methods for well completions
WO2017156012A1 (en) 2016-03-07 2017-09-14 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
WO2017173054A1 (en) 2016-03-30 2017-10-05 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
US9796756B2 (en) 2010-12-17 2017-10-24 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
WO2017223135A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
WO2018009838A1 (en) 2016-07-07 2018-01-11 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
US9867888B2 (en) 2015-09-17 2018-01-16 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2018102740A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
WO2018151829A1 (en) 2017-02-17 2018-08-23 Rubius Therapeutics, Inc. Functionalized erythroid cells
US10086013B2 (en) 2011-10-27 2018-10-02 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
WO2018208728A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2019051289A1 (en) 2017-09-08 2019-03-14 Generation Bio Co. FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS
WO2019067992A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. Formulations
WO2019067910A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
US20190240349A1 (en) 2015-06-19 2019-08-08 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US10450568B2 (en) 2015-10-09 2019-10-22 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2019217941A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of suppressing pathogenic mutations using programmable base editor systems
US10562849B2 (en) 2016-05-16 2020-02-18 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020081938A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
US10808246B2 (en) 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
WO2020243560A1 (en) * 2019-05-31 2020-12-03 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795200B (zh) * 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
KR102930465B1 (ko) * 2017-11-02 2026-02-25 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 ACE-tRNA를 이용한 유전 재할당을 통한 정지 코돈의 구조 방법

Patent Citations (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US99823A (en) 1870-02-15 Improved indigo soap
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4981957A (en) 1984-07-19 1991-01-01 Centre National De La Recherche Scientifique Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US4845205A (en) 1985-01-08 1989-07-04 Institut Pasteur 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5286717A (en) 1987-03-25 1994-02-15 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5552540A (en) 1987-06-24 1996-09-03 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5405939A (en) 1987-10-22 1995-04-11 Temple University Of The Commonwealth System Of Higher Education 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine
US5519126A (en) 1988-03-25 1996-05-21 University Of Virginia Alumni Patents Foundation Oligonucleotide N-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5453496A (en) 1988-05-26 1995-09-26 University Patents, Inc. Polynucleotide phosphorodithioate
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5466786B1 (en) 1989-10-24 1998-04-07 Gilead Sciences 2' Modified nucleoside and nucleotide compounds
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5466786A (en) 1989-10-24 1995-11-14 Gilead Sciences 2'modified nucleoside and nucleotide compounds
US5455233A (en) 1989-11-30 1995-10-03 University Of North Carolina Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5750692A (en) 1990-01-11 1998-05-12 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5587469A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides containing N-2 substituted purines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US6239265B1 (en) 1990-01-11 2001-05-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5563253A (en) 1990-03-08 1996-10-08 Worcester Foundation For Biomedical Research Linear aminoalkylphosphoramidate oligonucleotide derivatives
US5536821A (en) 1990-03-08 1996-07-16 Worcester Foundation For Biomedical Research Aminoalkylphosphorothioamidate oligonucleotide deratives
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5567811A (en) 1990-05-03 1996-10-22 Amersham International Plc Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5514785A (en) 1990-05-11 1996-05-07 Becton Dickinson And Company Solid supports for nucleic acid hybridization assays
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5677439A (en) 1990-08-03 1997-10-14 Sanofi Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5177195A (en) 1991-01-08 1993-01-05 Imperial Chemical Industries Plc Disazo dyes
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5393878A (en) 1991-10-17 1995-02-28 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5319080A (en) 1991-10-17 1994-06-07 Ciba-Geigy Corporation Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US6380368B1 (en) 1991-11-26 2002-04-30 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6326199B1 (en) 1991-12-24 2001-12-04 Isis Pharmaceuticals, Inc. Gapped 2′ modified oligonucleotides
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5639873A (en) 1992-02-05 1997-06-17 Centre National De La Recherche Scientifique (Cnrs) Oligothionucleotides
US5541316A (en) 1992-02-11 1996-07-30 Henkel Kommanditgesellschaft Auf Aktien Process for the production of polysaccharide-based polycarboxylates
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5610300A (en) 1992-07-01 1997-03-11 Ciba-Geigy Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5700920A (en) 1992-07-01 1997-12-23 Novartis Corporation Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US6683167B2 (en) 1992-07-23 2004-01-27 University Of Massachusetts Worcester Hybrid oligonucleotide phosphorothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5466677A (en) 1993-03-06 1995-11-14 Ciba-Geigy Corporation Dinucleoside phosphinates and their pharmaceutical compositions
US5576427A (en) 1993-03-30 1996-11-19 Sterling Winthrop, Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5663312A (en) 1993-03-31 1997-09-02 Sanofi Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
US5658873A (en) 1993-04-10 1997-08-19 Degussa Aktiengesellschaft Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions containing them
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028188A (en) 1993-11-16 2000-02-22 Genta Incorporated Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5446137A (en) 1993-12-09 1995-08-29 Syntex (U.S.A.) Inc. Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US6169170B1 (en) 1994-03-18 2001-01-02 Lynx Therapeutics, Inc. Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6124445A (en) 1994-11-23 2000-09-26 Isis Pharmaceuticals, Inc. Phosphotriester oligonucleotides, amidities and method of preparation
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
USRE39464E1 (en) 1998-07-14 2007-01-09 Isis Pharmaceuticals Inc. Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6858715B2 (en) 1999-02-04 2005-02-22 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7041816B2 (en) 1999-02-04 2006-05-09 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6534639B1 (en) 1999-07-07 2003-03-18 Isis Pharmaceuticals, Inc. Guanidinium functionalized oligonucleotides and method/synthesis
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7321029B2 (en) 2000-01-21 2008-01-22 Geron Corporation 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
US20050175682A1 (en) 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20060008378A1 (en) 2004-04-30 2006-01-12 Kunihiro Imai Sterilization method
WO2006045116A2 (en) * 2004-10-20 2006-04-27 The Scripps Research Institute In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
US20100062967A1 (en) 2004-12-27 2010-03-11 Silence Therapeutics Ag Coated lipid complexes and their use
US20080020058A1 (en) 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20080042973A1 (en) 2006-07-10 2008-02-21 Memsic, Inc. System for sensing yaw rate using a magnetic field sensor and portable electronic devices using the same
US8828956B2 (en) 2007-12-04 2014-09-09 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8106022B2 (en) 2007-12-04 2012-01-31 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US9867882B2 (en) 2007-12-04 2018-01-16 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US20100130588A1 (en) 2008-04-15 2010-05-27 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20120128767A1 (en) 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
US20110256175A1 (en) 2008-10-09 2011-10-20 The University Of British Columbia Amino lipids and methods for the delivery of nucleic acids
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US20120027796A1 (en) 2008-11-10 2012-02-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
US20120058144A1 (en) 2008-11-10 2012-03-08 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
US20120095200A1 (en) 2009-06-05 2012-04-19 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by nucleic acid containing a dicer substrate and a receptor binding region
US8158601B2 (en) 2009-06-10 2012-04-17 Alnylam Pharmaceuticals, Inc. Lipid formulation
US20110076335A1 (en) 2009-07-01 2011-03-31 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20120202871A1 (en) 2009-07-01 2012-08-09 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US20120149894A1 (en) 2009-08-20 2012-06-14 Mark Cameron Novel cationic lipids with various head groups for oligonucleotide delivery
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
US20130338210A1 (en) 2009-12-07 2013-12-19 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US20130053572A1 (en) 2010-01-22 2013-02-28 Steven L. Colletti Novel Cationic Lipids for Oligonucleotide Delivery
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US20130116307A1 (en) 2010-05-12 2013-05-09 Protiva Biotherapeutics Inc. Novel cyclic cationic lipids and methods of use
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US20120027803A1 (en) 2010-06-03 2012-02-02 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130090372A1 (en) 2010-06-04 2013-04-11 Brian W. Budzik Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
US20130303587A1 (en) 2010-06-30 2013-11-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
WO2012030683A2 (en) 2010-08-31 2012-03-08 Merck Sharp & Dohme Corp. Novel single chemical entities and methods for delivery of oligonucleotides
US20130178541A1 (en) 2010-09-20 2013-07-11 Matthew G. Stanton Novel low molecular weight cationic lipids for oligonucleotide delivery
US20130274523A1 (en) 2010-09-30 2013-10-17 John A. Bawiec, III Low molecular weight cationic lipids for oligonucleotide delivery
US20120101478A1 (en) 2010-10-21 2012-04-26 Allergan, Inc. Dual Cartridge Mixer Syringe
US20130274504A1 (en) 2010-10-21 2013-10-17 Steven L. Colletti Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery
US20170210967A1 (en) 2010-12-06 2017-07-27 Schlumberger Technology Corporation Compositions and methods for well completions
US9796756B2 (en) 2010-12-17 2017-10-24 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
US20140200257A1 (en) 2011-01-11 2014-07-17 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012162210A1 (en) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Ring constrained cationic lipids for oligonucleotide delivery
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20150203446A1 (en) 2011-09-27 2015-07-23 Takeda Pharmaceutical Company Limited Di-aliphatic substituted pegylated lipids
US10086013B2 (en) 2011-10-27 2018-10-02 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
US9708628B2 (en) 2011-11-18 2017-07-18 Nof Corporation Cationic lipid having improved intracellular kinetics
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20150005363A1 (en) 2011-12-07 2015-01-01 Alnylam Pharmaceuticals, Inc. Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
US20130195920A1 (en) 2011-12-07 2013-08-01 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20140039032A1 (en) 2011-12-12 2014-02-06 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising cationic lipid for drug delivery system
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
US20150064242A1 (en) 2012-02-24 2015-03-05 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US20150057373A1 (en) 2012-03-27 2015-02-26 Sirna Therapeutics, Inc DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
US20150246133A1 (en) 2012-05-02 2015-09-03 Sima Therapeutics, Inc. Novel tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
WO2013166121A1 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
WO2013166155A1 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Novel tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
US20150203843A1 (en) 2012-05-02 2015-07-23 Sirna Therapeutics, Inc. Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
WO2014136086A1 (en) 2013-03-08 2014-09-12 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10808246B2 (en) 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US20150140070A1 (en) 2013-10-22 2015-05-21 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
US20150239926A1 (en) 2013-11-18 2015-08-27 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for rna delivery
US9644180B2 (en) 2013-11-18 2017-05-09 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US20150141678A1 (en) 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
US20160317458A1 (en) 2013-12-19 2016-11-03 Luis Brito Lipids and Lipid Compositions for the Delivery of Active Agents
WO2015095340A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US20160311759A1 (en) 2013-12-19 2016-10-27 Luis Brito Lipids and Lipid Compositions for the Delivery of Active Agents
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US20150376115A1 (en) 2014-06-25 2015-12-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
US20190240349A1 (en) 2015-06-19 2019-08-08 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US20160376224A1 (en) 2015-06-29 2016-12-29 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
US9867888B2 (en) 2015-09-17 2018-01-16 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US10450568B2 (en) 2015-10-09 2019-10-22 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US20170119904A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017083368A1 (en) 2015-11-12 2017-05-18 Pfizer Inc. Tissue-specific genome engineering using crispr-cas9
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
US20180028664A1 (en) 2015-12-10 2018-02-01 Modernatx, Inc. Compositions and methods for delivery of agents
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017123644A1 (en) 2016-01-11 2017-07-20 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for immune indications
WO2017123646A1 (en) 2016-01-11 2017-07-20 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cancer indications
WO2017156012A1 (en) 2016-03-07 2017-09-14 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
WO2017173054A1 (en) 2016-03-30 2017-10-05 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
US20190136231A1 (en) 2016-03-30 2019-05-09 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
US10562849B2 (en) 2016-05-16 2020-02-18 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
WO2017223135A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
WO2018009838A1 (en) 2016-07-07 2018-01-11 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2018102740A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
WO2018151829A1 (en) 2017-02-17 2018-08-23 Rubius Therapeutics, Inc. Functionalized erythroid cells
WO2018208728A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2019051289A9 (en) 2017-09-08 2019-05-23 Generation Bio Co. Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
WO2019051289A1 (en) 2017-09-08 2019-03-14 Generation Bio Co. FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS
WO2019067910A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
WO2019067992A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. Formulations
WO2019217941A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of suppressing pathogenic mutations using programmable base editor systems
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020081938A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
WO2020243560A1 (en) * 2019-05-31 2020-12-03 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools

Non-Patent Citations (50)

* Cited by examiner, † Cited by third party
Title
BENGSTROM M. ET AL., NUCLEOS. NUCLEOT. NUCL., vol. 9, 1990, pages 123 - 127
BENOIT, BIOMACROMOLECULES, vol. 12, 2011, pages 2708 - 2714
BIOORG. MED. CHEM, vol. 25, 2017, pages 3350 - 3356
CHENG ET AL., NAT NANOTECHNOL, vol. 15, no. 4, 2020, pages 313 - 320
COFFIN, J. M.: "Virology", 1996, LIPPINCOTT-RAVEN, article "Retroviridae: The viruses and their replication"
CUI ET AL., NUCLEIC ACIDS RES., vol. 46, no. 12, 2018, pages 6387 - 6400
DESNICK RJ ET AL., J LAB CLIN MED, vol. 81, 1973, pages 157 - 71
ELMEN, J, NUCLEIC ACIDS RESEARCH, vol. 33, no. l, 2005, pages 439 - 447
ENGLISCH ET AL., ANGEWANDTE CHEMIE, vol. 30, 1991, pages 613
GRUNWELLER, A. ET AL., NUCLEIC ACIDS RESEARCH, vol. 31, no. 12, 2003, pages 3185 - 3193
GUY, CS ET AL., NAT REV IMMUNOL, vol. 8, 2011, pages 874 - 887
HA ET AL., ACTA PHARMACEUTICA SINICA B, vol. 6, July 2016 (2016-07-01), pages 287 - 296, Retrieved from the Internet <URL:https://doi.org/10.1016/j.apsb.2016.02.001>
HARTSEL SA ET AL., OLIGONUCLEOTIDE SYNTHESIS, 2005, pages 033 - 050
HUANG ET AL., NATURE COMMUNICATIONS, vol. 8, 2017, pages 423
JAYARAMAN ET AL., ANGEW CHEM INT ED ENGL, vol. 51, no. 34, 2012, pages 8529 - 8533
JIA, B. ET AL., LIFE SCI, vol. 108, 2014, pages 22 - 29
KIM ET AL., METHODS MOL BIOL, vol. 721, 2011, pages 339 - 353
KOLHATKAR ET AL., CURR DRUG DISCOV TECHNOL, vol. 8, 2011, pages 197 - 206
LI ET AL., NANOMATERIALS, vol. 7, 2017, pages 122
LIN ET AL., NUCLEIC ACIDS RESEARCH, vol. 47, no. W1, 2 July 2019 (2019-07-02), pages W542 - W547
MARTIN ET AL., HELV. CHIM. ACTA, vol. 78, 1995, pages 486 - 504
MATSUBARA TERUHIKO ET AL: "Incorporation of glycosylated amino acid into protein by an in vitro translation system", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 20, 15 August 2013 (2013-08-15), pages 5634 - 5636, XP028731075, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.08.035 *
MATULIC-ADAMIC JASENKA ET AL: "Synthesis of N-acetyl-D-galactosamine and folic acid conjugated ribozymes", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 13, no. 5, 10 July 2002 (2002-07-10), pages 1071 - 1078, XP002521069, ISSN: 1043-1802, [retrieved on 20020710], DOI: 10.1021/BC025525Q *
MOOK, OR. ET AL., MOL CANE THER, vol. 6, no. 3, 2007, pages 833 - 843
MUSACCHIOTORCHILIN, FRONT BIOSCI, vol. 16, 2011, pages 1388 - 1412
NAIR K, J. AM. CHEM. SOC, vol. 134, no. 49, 2014, pages 16958 - 16961
NEUNER SANDRO ET AL: "Synthesis of aminoacylatedN6,N6-dimethyladenosine solid support for efficient access to hydrolysis-resistant 3'-charged tRNA mi", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 24, 13 October 2014 (2014-10-13), pages 6989 - 6995, XP029102525, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2014.09.054 *
NIELSEN ET AL., SCIENCE, vol. 254, 1991, pages 1497 - 1500
OGAWA ATSUSHI ET AL: "A Novel Label-Free Biosensor Using an Aptazyme-Suppressor-tRNA Conjugate and an Amber Mutated Reporter Gene", CHEMBIOCHEM, vol. 9, no. 14, 22 September 2008 (2008-09-22), pages 2204 - 2208, XP055914140, ISSN: 1439-4227, DOI: 10.1002/cbic.200800294 *
PARK I. ET AL., NATURE, vol. 451, 2008, pages 141 - 146
PATIL ET AL., CRIT REV THER DRUG CARRIER SYST, vol. 25, 2008, pages 1 - 61
PEER ET AL., PROC NATL ACAD SCI USA., vol. 104, 2007, pages 4095 - 4100
PEER ET AL., SCIENCE, vol. 319, 2008, pages 627 - 630
PEER, J CONTROL RELEASE, vol. 20, 2010, pages 63 - 68
PEERLIEBERMAN, GENE THER, vol. 18, 2011, pages 1127 - 1133
SANGHVI, Y S.: "dsRNA Research and Applications", 1993, CRC PRESS, pages: 276 - 278
SCARINGE S. ET AL., CURR PROTOC NUCLEIC ACID CHEM, 2004
SHI ET AL., PROC NATL ACAD SCI USA., vol. 111, no. 28, 2014, pages 10131 - 10136
SONG ET AL., NAT BIOTECHNOL., vol. 23, 2005, pages 709 - 717
SPUCHNAVARRO, JOURNAL OF DRUG DELIVERY, vol. 2011, 2011, pages 12
SRINIVASAN ET AL., METHODS MOL BIOL, vol. 757, 2012, pages 497 - 507
SUBRAMANYA ET AL., MOL THER, vol. 18, no. 7, 2010, pages 2028 - 2037
TAKAHASHI, K.YAMANAKA, S.: "126", CELL, 2006, pages 663 - 676
TEMPLETON ET AL., NATURE BIOTECH, vol. 15, 1997, pages 647 - 652
USMAN N. ET AL., J. AM. CHEM. SOC, vol. 109, 1987, pages 7845 - 7854
XU RAN ET AL: "Site-specific incorporation of the mucin-type N-acetylgalactosamine-alpha-O-threonine into protein in Escherichia coli", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, vol. 126, no. 48, 11 November 2004 (2004-11-11), pages 15654 - 15655, XP002515396, ISSN: 0002-7863, DOI: 10.1021/JA044711Z *
YANG J. ET AL., J VIRAL HEPAT, vol. 13, 2006, pages 158 - 165
YU ET AL., MOL MEMBR BIOL, vol. 27, 2010, pages 286 - 298
YUANYU HUANG: "Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 6, 14 December 2016 (2016-12-14), US, pages 116 - 132, XP055485332, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2016.12.003 *
ZHAO ET AL., EXPERT OPIN DRUG DELIV, vol. 5, 2008, pages 309 - 319

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023064513A3 (en) * 2021-10-13 2023-06-15 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use
WO2023250112A1 (en) * 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024216191A1 (en) * 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
WO2025196508A1 (en) * 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Targeted delivery of therapeutic agents to hepatocytes

Also Published As

Publication number Publication date
IL303886A (en) 2023-08-01
JP2024501288A (ja) 2024-01-11
TW202242108A (zh) 2022-11-01
US20240175020A1 (en) 2024-05-30
CA3206285A1 (en) 2022-06-30
AU2021409740A9 (en) 2024-09-12
AU2021409740A1 (en) 2023-07-06
KR20230135585A (ko) 2023-09-25
MX2023007630A (es) 2023-08-25
BR112023012377A2 (pt) 2023-10-24
EP4267732A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
AU2021409740A1 (en) Compositions of modified trems and uses thereof
US12121531B2 (en) TREM compositions and uses thereof
WO2021243290A1 (en) Trem compositions and methods relating thereto
TW202317151A (zh) 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
TW202313069A (zh) 用於治療或預防斯特格氏症及／或視黃醛－相關疾患的組成物及方法
KR20240107319A (ko) Trem 조성물 및 사용 방법
WO2025042786A1 (en) Compositions comprising circular polyribonucleotides and uses thereof
US20250179492A1 (en) Compositions of modified trems and uses thereof
CN117083383A (zh) 经修饰的trem的组合物及其用途
US20250295687A1 (en) Trem compositions and methods of use for treating proliferative disorders
US20230203509A1 (en) Trem compositions and methods relating thereto
WO2026080471A2 (en) Compositions of trem conjugates and uses thereof
WO2024216206A2 (en) Trem compositions and methods of use
WO2024216191A1 (en) Modified trems, compositions, and related methods thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21854913

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3206285

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023538736

Country of ref document: JP

Ref document number: MX/A/2023/007630

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023012377

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021409740

Country of ref document: AU

Date of ref document: 20211223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202317046602

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021854913

Country of ref document: EP

Effective date: 20230724

WWE Wipo information: entry into national phase

Ref document number: 202180094267.X

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023012377

Country of ref document: BR

Free format text: APRESENTAR NOVO CONTEUDO ELETRONICO DE LISTAGEM DE SEQUENCIAS BIOLOGICAS, UMA VEZ QUE O ARQUIVO APRESENTADO TEM INCORRECAO NO CAMPO 110.

ENP Entry into the national phase

Ref document number: 112023012377

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230621